Europäisches Patentamt

European Patent Office

·



Office européen des brevets (11) EP 0 669 836 B1

(12) EUROPEAN PATENT SPECIFICATION

- (45) Date of publication and mention of the grant of the patent: 03.07.1996 Bulletin 1996/27
- (21) Application number: 94901444.3
- (22) Date of filing: 12.11.1993

- (51) Int. Cl.⁶: **A61K 39/395**, A61K 51/00, C12N 15/02, C12P 21/08
- (86) International application number: PCT/US93/10953
- (87) International publication number: WO 94/11026 (26.05.1994 Gazette 1994/12)
- (54) THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

THERAPEUTISCHE VERWENDUNG VON CHIMERISCHEN UND MARKIERTEN ANTIKÖRPER GEGEN MENSCHLICHEN B LYMPHOZYT BESCHRÄNKTER DIFFERENZIERUNG ANTIGEN FÜR DIE BEHANDLUNG VON B-ZELL-LYMPHOMA

APPLICATION THERAPEUTIQUE D'ANTICORPS CHIMERIQUES ET RADIO-MARQUES CONTRE L'ANTIGENE A DIFFERENTIATION RESTREINTE DES LYMPHOCYTES B HUMAINS POUR LE TRAITEMENT DU LYMPHOME DES CELLULES B

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

- (30) Priority: 13.11.1992 US 978891 03.11.1993 US 149099
- (43) Date of publication of application: 06.09.1995 Bulletin 1995/36
- (60) Divisional application: 96200772.0
- (73) Proprietor: IDEC PHARMACEUTICALS
 CORPORATION
 San Diego, CA 92121-1104 (US)
- (72) Inventors:
 - ANDERSON, Darrell, R. Escondido, CA 92029 (US)
 - RASTETTER, William, H.
 Rancho Santa Fe, CA 92067 (US)
 - HANNA, Nabil Olivenhain, CA 92024 (US)
 - LEONARD, John, E. Encinitas, CA 92024 (US)

- NEWMAN, Roland, A. San Diego, CA 92122 (US)
- REFF, Mitchell, E. San Diego, CA 92122 (US)
- (74) Representative: Daniels, Jeffrey Nicholas et al Page White & Farrer
 54 Doughty Street London WC1N 2LS (GB)
- (56) References cited: EP-A- 0 274 394
 - JOURNAL OF IMMUNOLOGY vol. 139, no. 10, 15
 November 1987, BALTIMORE US pages 3521 3526 ALVIN Y. LIU ET AL. 'PRODUCTION OF A
 MOUSE-HUMAN CHIMERIC MONOCLONAL
 ANTIBODY TO CD20 WITH POTENT FC DEPENDENT BIOLOGIC ACTIVITY.' cited in the
 application

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

5

15

25

30

A. FIELD OF THE INVENTION

The references to be discussed throughout this document are set forth merely for the information described therein prior to the filing dates of this document, and nothing herein is to be construed as an admission, either express or implied, that the references are "prior art" or that the inventors are not entitled to antedate such descriptions by virtue of prior inventions or priority based on earlier filed applications.

The present invention is directed to the treatment of B cell lymphoma using chimeric and radiolabeled antibodies to the B cell surface antigen Bp35 ("CD20").

B. BACKGROUND OF THE INVENTION

The immune system of vertebrates (for example, primates, which include humans, apes, monkeys, etc.) consists of a number of organs and cell types which have evolved to: accurately and specifically recognize foreign microorganisms ("antigen") which invade the vertebrate-host; specifically bind to such foreign microorganisms; and, eliminate/destroy such foreign microorganisms. Lymphocytes, amongst others, are critical to the immune system. Lymphocytes are produced in the thymus, spleen and bone marrow (adult) and represent about 30% of the total white blood cells present in the circulatory system of humans (adult). There are two major sub-populations of lymphocytes: T cells and B cells. T cells are responsible for cell mediated immunity, while B cells are responsible for antibody production (humoral immunity). However, T cells and B cells can be considered as interdependent--in a typical immune response, T cells are activated when the T cell receptor binds to fragments of an antigen that are bound to major histocompatability complex ("MHC") glycoproteins on the surface of an antigen presenting cell; such activation causes release of biological mediators ("interleukins") which, in essence, stimulate B cells to differentiate and produce antibody ("immunoglobulins") against the antigen.

Each B cell within the host expresses a different antibody on its surface - thus, one B cell will express antibody specific for one antigen, while another B cell will express antibody specific for a different antigen. Accordingly, B cells are quite diverse, and this diversity is critical to the immune system. In humans, each B cell can produce an enormous number of antibody molecules (*ie* about 10⁷ to 10⁸). Such antibody production most typically ceases (or substantially decreases) when the foreign antigen has been neutralized. Occasionally, however, proliferation of a particular B cell will continue unabated; such proliferation can result in a cancer referred to as "B cell lymphoma."

T cells and B cells both comprise cell surface proteins which can be utilized as "markers" for differentiation and identification. One such human B cell marker is the human B lymphocyte-restricted differentiation antigen Bp35, referred to as "CD20." CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. Specifically, the CD20 molecule may regulate a step in the activation process which is required for cell cycle initiation and differentiation and is usually expressed at very high levels on neoplastic ("tumor") B cells. CD20, by definition, is present on both "normal" B cells as well as "malignant" B cells, *ie* those B cells whose unabated proliferation can lead to B cell lymphoma. Thus, the CD20 surface antigen has the potential of serving as a candidate for "targeting" of B cell lymphomas.

In essence, such targeting can be generalized as follows: antibodies specific to the CD20 surface antigen of B cells are, *eg* injected into a patient. These anti-CD20 antibodies specifically bind to the CD20 cell surface antigen of (ostensibly) both normal and malignant B cells; the anti-CD20 antibody bound to the CD20 surface antigen may lead to the destruction and depletion of neoplastic B cells. Additionally, chemical agents or radioactive labels having the potential to destroy the tumor can be conjugated to the anti-CD20 antibody such that the agent is specifically "delivered" to, e.g. the neoplastic B cells. Irrespective of the approach, a primary goal is to destroy the tumor: the specific approach can be determined by the particular anti-CD20 antibody which is utilized and, thus, the available approaches to targeting the CD20 antigen can vary considerably.

For example, attempts at such targeting of CD20 surface antigen have been reported. Murine (mouse) monoclonal antibody 1F5 (an anti-CD20 antibody) was reportedly administered by continuous intravenous infusion to B cell lymphoma patients. Extremely high levels (>2 grams) of 1F5 were reportedly required to deplete circulating tumor cells, and the results were described as being "transient." Press *et al.*, "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B-Cell Lymphomas." *Blood 69/2:*584-591(1987). A potential problem with this approach is that non-human monoclonal antibodies (*eg,* murine monoclonal antibodies) typically lack human effector functionality, *ie* they are unable to, *inter alia*, mediate complement dependent lysis or lyse human target cells through antibody dependent cellular toxicity or Fc-receptor mediated phagocytosis. Furthermore, non-human monoclonal antibodies can be recognized by the human host as a foreign protein; therefore, repeated injections of such foreign antibodies can lead to the induction of immune responses leading to harmful hypersensitivity reactions. For murine-based monoclonal antibodies, this is often referred to as a Human Anti-Mouse Antibody response, or "HAMA" response. Additionally, these "foreign" antibodies

can be attacked by the immune system of the host such that they are, in effect, neutralized before they reach their target site.

Lymphocytes and lymphoma cells are inherently sensitive to radiotherapy for several reasons: the local emission of ionizing radiation of radiolabeled antibodies may kill cells with or without the target antigen (eg, CD20) in close proximity to antibody bound to the antigen; penetrating radiation may obviate the problem of limited access to the antibody in bulky or poorly vascularized tumors; and, the total amount of antibody required may be reduced. The radionuclide emits radioactive particles which can damage cellular DNA to the point where the cellular repair mechanisms are unable to allow the cell to continue living; therefore, if the target cells are tumors, the radioactive label beneficially kills the tumor cells. Radiolabeled antibodies, by definition, include the use of a radioactive substance which may require the need for precautions for both the patient (ie possible bone marrow transplantation) as well as the health care provider (ie the need to exercise a high degree of caution when working with the radioactivity).

Therefore, an approach at improving the ability of murine monoclonal antibodies to be effective in the treatment of B-cell disorders has been to conjugate a radioactive label or toxin to the antibody such that the label or toxin is localized at the tumor site. For example, the above-referenced IF5 antibody has been "labeled" with iodine-131 ("¹³¹I") and was reportedly evaluated for biodistribution in two patients. *See* Eary, J.F. *et al.*, "Imaging and Treatment of B-Cell Lymphoma" *J. Nuc. Med. 31*/8:1257-1268 (1990); *see also*, Press, O.W. *et al.*, "Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody" *J. Clin. Onc. 7*/8:1027-1038 (1989) (indication that one patient treated with ¹³¹I-labeled IF-5 achieved a "partial response"); Goldenberg, D.M. *et al.*, "Targeting, Dosimetry and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody" *J. Clin. Onc. 9*/4:548-564 (1991) (three of eight patients receiving multiple injection reported to have developed a HAMA response); Appelbaum, F.R. "Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma" *Hem.JOnc. Clinics of N.A. 5*/5:1013-1025 (1991) (review article); Press, O.W. *et al* "Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support." *New England Journal of Medicine 329*/17: 1219-12223 (1993) (iodine-131 labeled anti-CD20 antibody IF5 and B1); and Kaminski, M.G. et al "Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I] Anti-B1 (Anti-CD20) Antibody". *NEJM 329*/7 (1993) (iodine-131 labeled anti-CD20 antibody B1; hereinafter "Kaminski").

Toxins (*ie* chemotherapeutic agents such as doxorubicin or mitomycin C) have also been conjugated to antibodies. *See, for example,* PCT published application WO 92/07466 (published May 14, 1992).

"Chimeric" antibodies, *ie* antibodies which comprise portions from two or more different species (*eg*, mouse and human) have been developed as an alternative to "conjugated" antibodies. For example, Liu, A.Y. *et al.*, "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity" *J. Immun.* 139/10:3521-3526 (1987), describes a mouse/human chimeric antibody directed against the CD20 antigen. *See also*, PCT Publication No. WO 88/04936. However, no information is provided as to the ability, efficacy or practicality of using such chimeric antibodies for the treatment of B cell disorders in the reference. It is noted that *in vitro* functional assays (*eg* complement dependent lysis ("CDC"); antibody dependent cellular cytotoxicity ("ADCC"), etc.) cannot inherently predict the *in vivo* capability of a chimeric antibody to destroy or deplete target cells expressing the specific antigen. *See*, for example, Robinson, R.D. *et al.*, "Chimeric mouse-human anti-carcinoma antibodies that mediate different antitumor cell biological activities," *Hum. Antibod. Hybridomas 2*:84-93 (1991) (chimeric mouse-human antibody can only truly be assessed by *in vivo* experimentation.

EP-A-274394 published on July 13, 1988 which names Oncogen and International Genetic Engineering, Inc. as Co-Applicants describes a specific chimeric antibody with specificity to a human B cell surface antigen (CD20) expressed on human B cells. The application alleges that this antibody may be used to treat or prevent B cell disorders including lymphomas. However, there is no <u>in vivo</u> data in the application to substantiate this allegation.

What is needed, and what would be a great advance in the art, are therapeutic approaches targeting the CD20 antigen for the treatment of B cell lymphomas in primates, including, but not limited to, humans.

C. SUMMARY OF THE INVENTION

25

40

Disclosed herein are therapeutic methods designed or the treatment of B cell disorders, and in particular, B cell lymphomas. These protocols are based upon the administration of immunologically active chimeric anti-CD20 antibodies for the depletion of peripheral blood B cells, including B cells associated with lymphoma; administration or radiolabeled anti-CD20 antibodies for targeting localized and peripheral B cell associated tumors; and administration of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies in a cooperative therapeutic strategy.

D. BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagrammatic representation of a tandem chimeric antibody expression vector useful in the production of immunologically active chimeric anti-CD20 antibodies ("TCAE 8");

Figures 2A through 2E are the nucleic acid sequence of the vector of Figure 1;

5

10

15

20

25

30

35

Figures 3A through 3F are the nucleic acid sequence of the vector of Figure 1 further comprising murine light and heavy chain variable regions ("anti-CD20 in TCAE 8");

Figure 4 is the nucleic acid and amino acid sequences (including CDR and framework regions) of murine variable region light chain derived from murine anti-CD20 monoclonal antibody 2B8;

Figure 5 is the nucleic acid and amino acid sequences (including CDR and framework regions) of murine variable region heavy chain derived from murine anti-CD20 monoclonal antibody 2B8;

Figure 6 are flow cytometry results evidencing binding of fluorescent-labeled human C1q to chimeric anti-CD20 antibody, including, as controls labeled C1q; labeled C1q and murine anti-CD20 monoclonal antibody 2B8; and labeled C1q and human lgGl,k;

Figure 7 represents the results of complement related lysis comparing chimeric anti-CD20 antibody and murine anti-CD20 monoclonal antibody 2B8;

Figure 8 represents the results of antibody mediated cellular cytotoxicity with *in vivo* human effector cells comparing chimeric anti-CD20 antibody and 2B8;

Figure 9A, 9B and 9C provide the results of non-human primate peripheral blood B lymphocyte depletion after infusion of 0.4 mg/kg (A); 1.6 mg/kg (B); and 6.4 mg/kg (C) of immunologically active chimeric anti-CD20 antibody;

Figure 10 provides the results of, *inter alia*, non-human primate peripheral blood B lymphocyte depletion after infusion of 0.01 mg/kg of immunologically active chimeric anti-CD20 antibody;

Figure 11 provides results of the tumoricidal impact of Y2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;

Figure 12 provides results of the tumoricidal impact of C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;

Figure 13 provides results of the tumoricidal impact of a combination of Y2B8 and C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor; and

Figures 14A and 14B provide results from a Phase I/II clinical analysis of C2B8 evidencing B-cell population depletion over time for patients evidencing a partial remission of the disease (14A) and a minor remission of the disease (14B).

40 <u>E. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS</u>

Generally, antibodies are composed of two light chains and two heavy chain molecules; these chains form a general "Y" shape, with both light and heavy chains forming the arms of the Y and the heavy chains forming the base of the Y. Light and heavy chains are divided into domains of structural and functional homology. The variable domains of both the light ("V_L") and the heavy ("V_H") chains determine recognition and specificity. The constant region domains of light ("C_L") and heavy ("C_H") chains confer important biological properties, *eg* antibody chain association, secretion, transplacental mobility, Fc receptor binding complement binding, etc. The series of events leading to immunoglobulin gene expression in the antibody producing cells are complex. The variable domain region gene sequences are located in separate germ line gene segments referred to as "V_H," "D," and "J_H," or "V_L" and "J_L." These gene segments are joined by DNA rearrangements to form the complete V regions expressed in heavy and light chains, respectively. The rearranged, joined V segments (V_L-J_L and V_H-D-J_H) then encode the complete variable regions or antigen binding domains of light and heavy chains, respectively.

Serotherapy of human B cell lymphomas using an anti-CD20 murine monoclonal antibody (1F5) has been described by Press *et al.*, (69 *Blood* 584, 1987, *supra*); the reported therapeutic responses, unfortunately, were transient. Additionally, 25% of the tested patients reportedly developed a human anti-mouse antibody (HAMA) response to the serotherapy. Press *et al.*, suggest that these antibodies, conjugated to toxins or radioisotopes, might afford a more lasting clinical benefit than the unconjugated antibody.

Owing to the debilitating effects of B cell lymphoma and the very real need to provide viable treatment approaches to this disease, we have embarked upon different approaches having a particular antibody, 2B8, as the common link

between the approaches. One such approach advantageously exploits the ability of mammalian systems to readily and efficiently recover peripheral blood B cells; using this approach, we seek to, in essence, purge or deplete B cells in peripheral blood and lymphatic tissue as a means of also removing B cell lymphomas. We accomplish this by utilization of, *inter alia*, immunologically active, chimeric anti-CD20 antibodies. In another approach, we seek to target tumor cells for destruction with radioactive labels.

5

15

20

30

35

40

45

As used herein, the term "anti-CD20 antibody" is an antibody which specifically recognizes a cell surface nonglycosylated phosphoprotein of 35,000 Daltons, typically designated as the human B lymphocyte restricted differentiation antigen Bp35, commonly referred to as CD20. As used herein, the term "chimeric" when used in reference to anti-CD20 antibodies, encompasses antibodies which are most preferably derived using recombinant deoxyribonucleic acid techniques and which comprise both human (including immunologically "related" species, eg, chimpanzee) and non-human components: the constant region of the chimeric antibody is most preferably substantially identical to the constant region of a natural human antibody; the variable region of the chimeric antibody is most preferably derived from a non-human source and has the desired antigenic and specificity to the CD20 cell surface antigen. The non-human source can be any vertebrate source which can be used to generate antibodies to a human CD20 cell surface antigen or material comprising a human CD20 cell surface antigen. Such non-human source includes, but is not limited to, rodents (eg, rabbit, rat, mouse, etc.) and non-human primates (eg, Old World Monkey, Ape, etc.). Most preferably, the non-human component (variable region) is derived from a murine source. As used herein, the phrase "immunologically active" when used in reference to chimeric anti-CD20 antibodies, means a chimeric antibody which binds human C1q, mediates complement dependent lysis ("CDC") of human B lymphoid cell lines, and lyses human target cells through antibody dependent cellular cytotoxicity ("ADCC"). As used herein, the phrases "indirect labeling" and "indirect labeling approach" both mean that a chelating agent is covalently attached to an antibody and at least one radionuclide is inserted into the chelating agent. Preferred chelating agents and radionuclides are set forth in Srivagtava, S.C. and Mease, R.C., "Progress in Research on Ligands, Nuclides and Techniques for Labeling Monoclonal Antibodies," Nucl. Med. Bio. 1816: 589-603 (1991) ("Srivagtava") which is incorporated herein by reference. A particularly preferred chelating agent is 1-isothiocycmatobenzyl-3-methyldiothelene triaminepent acetic acid ("MX-DTPA"); particularly preferred radionuclides for indirect labeling include indium [111] and yttrium [90]. As used herein, the phrases "direct labeling" and "direct labeling approach" both mean that a radionuclide is covalently attached directly to an antibody (typically via an amino acid residue). Preferred radionuclides are provided in Srivagtava; a particularly preferred radionuclide for direct labeling is iodine [131] covalently attached via tyrosine residues. The indirect labeling approach is particularly preferred.

The therapeutic approaches disclosed herein are based upon the ability of the immune system of primates to rapidly recover, or rejuvenate, peripheral blood B cells. Additionally, because the principal immune response of primates is occasioned by T cells, when the immune system has a peripheral blood B cell deficiency, the need for "extraordinary" precautions (*ie* patient isolation, etc.) is not necessary. As a result of these and other nuances of the immune systems of primates, our therapeutic approach to B cell disorders allows for the purging of peripheral blood B cells using immunologically active chimeric anti-CD20 antibodies.

Because peripheral blood B cell disorders, by definition, can indicate a necessity for access to the blood for treatment, the route of administration of the immunologically active chimeric anti-CD20 antibodies and radioalabeled anti-CD20 antibodies is preferably parenteral; as used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal administration. Of these, intravenous administration is most preferred.

The immunologically active chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies will typically be provided by standard technique within a pharmaceutically acceptable buffer, for example, sterile saline, sterile buffered water, propylene glycol, combinations of the foregoing, etc. Methods for preparing parenterally administerable agents are described in *Pharmaceutical Carriers & Formulations*, Martin, Remington's Pharmaceutical Sciences, 15th Ed. (Mack Pub. Co., Easton, PA 1975), which is incorporated herein by reference.

The specific, therapeutically effective amount of immunologically active chimeric anti-CD20 antibodies useful to produce a unique therapeutic effect in any given patient can be determined by standard techniques well known to those of ordinary skill in the art.

Effective dosages (*ie* therapeutically effective amounts) of the immunologically active chimeric anti-CD20 antibodies range from about 0.001 to about 30 mg/kg body weight, more preferably from about 0.01 to about 25 mg/kg body weight, and most preferably from about 0.4 to about 20.0 mg/kg body weight. Other dosages are viable; factors influencing dosage include, but are not limited to, the severity of the disease; previous treatment approaches; overall health of the patient; other diseases present, etc. The skilled artisan is readily credited with assessing a particular patient and determining a suitable dosage that falls within the ranges, or if necessary, outside of the ranges.

Introduction of the immunologically active chimeric anti-CD20 antibodies in these dose ranges can be carried out as a single treatment or over a series of treatments. With respect to chimeric antibodies, it is preferred that such introduction be carried out over a series of treatments; this preferred approach is predicated upon the treatment methodology associated with this disease. While not wishing to be bound by any particular theory, because the immunologically active chimeric anti-CD20 antibodies are both immunologically active and bind to CD20, upon initial introduction of the immunologically active chimeric anti-CD20 antibodies to the individual, peripheral blood B cell depletion will begin; we have

observed a nearly complete depletion within about 24 hours post treatment infusion. Because of this, subsequent introduction(s) of the immunologically active chimeric anti-CD20 antibodies (or radiolabeled anti-CD20 antibodies) to the patient is presumed to: a) clear remaining peripheral blood B cells; b) begin B cell depletion from lymph nodes; c) begin B cell depletion from other tissue sources, *eg*, bone marrow, tumor, etc. Stated again, by using repeated introductions of the immunologically active chimeric anti-CD20 antibodies, a series of events take place, each event being viewed by us as important to effective treatment of the disease. The first "event" then, can be viewed as principally directed to substantially depleting the patient's peripheral blood B cells; the subsequent "events" can be viewed as either principally directed to simultaneously or serially clearing remaining B cells from the system clearing lymph node B cells, or clearing other tissue B cells.

In effect, while a single dosage provides benefits and can be effectively utilized for disease treatment/management, a preferred treatment course can occur over several stages; most preferably, between about 0.4 and about 20 mg/kg body weight of the immunologically active chimeric anti-CD20 antibodies is introduced to the patient once a week for between about 2 to 10 weeks, most preferably for about 4 weeks.

10

15

20

With reference to the use of radiolabeled anti-CD20 antibodies, a preference is that the antibody is non-chimeric; this preference is predicted upon the significantly longer circulating half-life of chimeric antibodies vis-a-vis murine antibodies (*ie* with a longer circulating half-life, the radionuclide is present in the patient for extended periods). However, radiolabeled chimeric antibodies can be beneficially utilized with lower milli-Curries ("mCi") dosages used in conjunction with the chimeric antibody relative to the murine antibody. This scenario allows for a decrease in bone marrow toxicity to an acceptable level, while maintaining therapeutic utility.

A variety of radionuclides are applicable to the present invention and those skilled in the art are credited with the ability to readily determine which radionuclide is most appropriate under a variety of circumstances. For example, iodine [131] is a well known radionuclide used for targeted immunotherapy. However, the clinical usefulness of iodine [131] can be limited by several factors including: eight-day physical half-life; dehalogenation of iodinated antibody both in the blood and at tumor sites; and emission characteristics (*eg* large gamma component) which can be suboptimal for localized dose deposition in tumor. With the advent of superior chelating agents, the opportunity for attaching metal chelating groups to proteins has increased the opportunities to utilize other radionuclides such as indium [131] and yttrium [90]. Yttrium [90] provides several benefits for utilization in radioimmunotherapeutic applications: the 64 hour half-life of yttrium [90] is long enough to allow antibody accumulation by tumor and, unlike *eg* iodine [131], yttrium [90] is a pure beta emitter of high energy with no accompanying gamma irradiation in its decay, with a range in tissue of 100 to 1000 cell diameters. Furthermore, the minimal amount of penetrating radiation allows for outpatient administration of yttrium [90]-labeled antibodies. Furthermore, interalization of labeled antibody is not required for cell killing, and the local emission of ionizing radiation should be lethal for adjacent tumor cells lacking the target antigen.

One non-therapeutic limitation to yttrium [90] is based upon the absence of significant gamma radiation making imaging therewith difficult. To avoid this problem, a diagnostic "imaging" radionuclide, such as indium [111], can be utilized for determining the location and relative size of a tumor prior to the administration of therapeutic does of yttrium [90]-labeled anti-CD20. Indium [111] is particularly preferred as the diagnostic radionuclide because: between about 1 to about 10mCi can be safely administered without detectable toxicity; and the imaging data is generally predictive of subsequent yttrium [90]-labeled antibody distribution. Most imaging studies utilize 5mCi indium [111]-labeled antibody because this dose is both safe and has increased imaging efficiency compared with lower doses, with optimal imaging occurring at three to six days after antibody administration. See, for example, Murray J.L., 26 J. Nuc. Med. 3328 (1985) and Carraguillo, J.A. et al, 26 J. Nuc. Med. 67 (1985).

Effective single treatment dosages (*ie* therapeutically effective amounts) of yttrium [90] labeled anti-CD20 antibodies range from between about 5 and about 75mCi, more preferably between about 10 and about 40mCi. Effective single treatment non-marrow ablative dosages of iodine [131] labeled anti-CD20 antibodies range from between about 5 and about 70mCi, more preferably between about 5 and about 40mCi. Effective single treatment ablative dosages (*ie* may require autologous bone marrow transplantation) of iodine [131] labeled anti-CD20 antibodies range from between about 30 and about 600mCi, more preferably between about 50 and less than about 500mCi. In conjunction with a chimeric anti-CD20 antibody, owing to the longer circulating half life vis-a-vis murine antibodies, an effective single treatment non-marrow ablative dosages of iodine [131] labeled chimeric anti-CD20 antibodies range from between about 5 and about 40mCi, more preferably less than about 30mCi. Imaging criteria for, *eg* the indium [111] label, are typically less than about 5mCi.

With respect to radiolabeled anti-CD20 antibodies, therapy therewith can also occur using a single therapy treatment or using multiple treatments. Because of the radionuclide component, it is preferred that prior to treatment, peripheral stem cells ("PSC") or bone marrow ("BM") be "harvested" for patients experiencing potentially fatal bone marrow toxicity resulting from radiation. BM and/or PSC are harvested using standard techniques, and then purged and frozen for possible reinfusion. Additionally, it is most preferred that prior to treatment a diagnostic dosimetry study using a diagnostic labeled antibody (eg using indium [111]) be conducted on the patient, a purpose of which is to ensure that the therapeutically labeled antibody (eg using yttrium [90]) will not become unnecessarily "concentrated" in any normal organ or tissue.

Chimeric mouse/human antibodies have been described. See, for example, Morrison, S.L. et al., PNAS 11:6851-6854 (November 1984); European Patent Publication No. 173 494; Boulianne, G.L. et al., Nature 312:643 (December, 1984); Neubeiger, M.S. et al., Nature 314:268 (March 1985); European Patent Publication No. 125023; Tan et al., J. Immunol. 135:8564 (November 1985); Sun, L.K. et al., Hybridoma 5/1:517 (1986); Sahagan et al., J. Immunol. 137:1066-1074 (1986). See generally, Muron, Nature 312:597 (December 1984); Dickson, Genetic Engineering News 5/3 (March 1985); Marx, Science 229 455 (August 1985); and Morrison Science 229:1202-1207 (September 1985). Robinson et al., in PCT Publication Number WO 88/04936 describe a chimeric antibody with human constant region and murine variable region, having specificity to an epitope of CD20; the murine portion of the chimeric antibody of the Robinson references is derived from the 2H7 mouse monoclonal antibody (gamma 2b, kappa). While the reference notes that the described chimeric antibody is a "prime candidate" for the treatment of B cell disorders, this statement can be viewed as no more than a suggestion to those in the art to determine whether or not this suggestion is accurate for this particular antibody, particularly because the reference lacks any data to support an assertion of therapeutic effectiveness, and importantly, data using higher order mammals such as primates or humans.

5

10

15

40

45

50

55

Methodologies for generating chimeric antibodies are available to those in the art. For example, the light and heavy chains can be expressed separately, using, for example, immunoglobulin light chain and immunoglobulin heavy chains in separate plasmids. These can then be purified and assembled *in vitro* into complete antibodies; methodologies for accomplishing such assembly have been described. *See*, for example; Scharff, M., *Harvey Lectures 69*:125 (1974). *In vitro* reaction parameters for the formation of IgG antibodies from reduced isolated light and heavy chains have also been described. *See*, for example, Beychok, S., *Cells of Immunoglobin Synthesis*, Academic Press, New York, p. 69, 1979. Co-expression of light and heavy chains in the same cells to achieve intracellular association and linkage of heavy and light chains into complete H₂L₂ IgG antibodies is also possible. Such co-expression can be accomplished using either the same or different plasmids in the same host cell.

Another approach, and one which is our most preferred approach for developing a chimeric non-human/human anti-CD20 antibody, is based upon utilization of an expression vector which includes, *ab initio*, DNA encoding heavy and light chain constant regions from a human source. Such a vector allows for inserting DNA encoding non-human variable region such that a variety of non-human anti-CD20 antibodies can be generated, screened and analyzed for various characteristics (*eg* type of binding specificity, epitope binding regions, etc.); thereafter, cDNA encoding the light and heavy chain variable regions from a preferred or desired anti-CD20 antibody can be incorporated into the vector. We refer to these types of vectors as Tandem Chimeric Antibody Expression ("TCAE") vectors. A most preferred TCAE vector which was used to generate immunologically active chimeric anti-CD20 antibodies for therapeutic treatment of lymphomas is TCAE 8. TCAE 8 is a derivative of a vector owned by the assignee of this patent document, referred to as TCAE 5.2 the difference being that in TCAE 5.2, the translation initiation start site of the dominant selectable marker (neomycin phosphostransferase, "NEO") is a consensus Kozak sequence, while for TCAE 8, this region is a partially impaired consensus Kozak sequence. Details regarding the impact of the initiation start site of the dominant selectable marker of the TCAE vectors (also referred to as "ANEX vector") vis-a-vis protein expression are disclosed in detail in the co-pending application filed herewith.

TCAE 8 comprises four (4) transcriptional cassettes, and these are in tandem order, *ie* a human immunoglobulin light chain absent a variable region; a human immunoglobulin heavy chain absent a variable region; DHFR; and NEO. Each transcriptional cassette contains its own eukaryotic promotor and polyadenylation region (reference is made to Figure 1 which is a diagrammatic representation of the TCAE 8 vector). Specifically:

- 1) the CMV promoter/enhancer in front of the immunoglobulin heavy chain is a truncated version of the promoter/enhancer in front of the light chain, from the Nhe I site at -350 to the Sst I site at -16 (see, 41 Cell 521, 1985).
- 2) a human immunoglobulin light chain constant region was derived via amplification of cDNA by a PCR reaction. In TCAE 8, this was the human immunoglobulin light chain kappa constant region (Kabat numbering, amino acids 108-214, allotype Km 3, (see, Kabat, E.A. "Sequences of proteins of immunological interest," NIH Publication, Fifth Ed. No. 91-3242, 1991)), and the human immunoglobulin heavy chain gamma 1 constant region (Kabat numbering amino acids 114-478, allotype Gmla, Gmlz). The light chain was isolated from normal human blood (IDEC Pharmaceuticals Corporation, La Jolla, CA); RNA therefrom was used to synthesize cDNA which was then amplified using PCR techniques (primers were derived vis-a-vis the consensus from Kabat). The heavy chain was isolated (using PCR techniques) from cDNA prepared from RNA which was in turn derived from cells transfected with a human IgG1 vector (see, 3 Prot. Eng. 531, 1990; vector pN $_{\gamma 1}$ 62). Two amino acids were changed in the isolated human IgG1 to match the consensus amino acid sequence from Kabat, to wit: amino acid 225 was changed from valine to alanine (GTT to GCA), and amino acid 287 was changed from methionine to lysine (ATG to AAG);
- 3) The human immunoglobulin light and heavy chain cassettes contain synthetic signal sequences for secretion of the immunoglobulin chains;

- 4) The human immunoglobulin light and heavy chain cassettes contain specific DNA restriction sites which allow for insertion of light and heavy immunoglobulin variable regions which maintain the transitional reading frame and do not alter the amino acids normally found in immunoglobulin chains;
- 5) The DHFR cassette contained its own eukaryotic promoter (mouse beta globin major promoter, "BETA") and polyadenylation region (bovine growth hormone polyadenylation, "BGH"); and
- 6) The NEO cassette contained its own eukaryotic promoter (BETA) and polyadenylation region (SV40 early polyadenylation, "SV").

With respect to the TCAE 8 vector and the NEO cassette, the Kozak region was a partially impaired consensus Kozak sequence (which included an upstream Cla I site):

ClaI -3 +1

GGGAGCTTGG ATCGAT ccTct ATG Gtt

(In the TCAE 5.2 vector, the change is between the Clal and ATG regions, to wit: ccAcc.)

5

10

15

20

30

The complete sequence listing of TCAE 8 (including the specific components of the four transcriptional cassettes) is set forth in Figure 2 (SEQ. ID. NO. 1).

As will be appreciated by those in the art, the TCAE vectors beneficially allow for substantially reducing the time in generating the immunologically active chimeric anti-CD20 antibodies. Generation and isolation of non-human light and heavy chain variable regions, followed by incorporation thereof within the human light chain constant transcriptional cassette and human heavy chain constant transcriptional cassette, allows for production of immunologically active chimeric anti-CD20 antibodies.

We have derived a most preferred non-human variable region with specificity to the CD20 antigen using a murine source and hybridoma technology. Using polymerase chain reaction ("PCR") techniques, the murine light and heavy variable regions were cloned directly into the TCAE 8 vector--this is the most preferred route for incorporation of the non-human variable region into the TCAE vector. This preference is principally predicated upon the efficiency of the PCR reaction and the accuracy of insertion. However, other equivalent procedures for accomplishing this task are available. For example, using TCAE 8 (or an equivalent vector), the sequence of the variable region of a non-human anti-CD20 antibody can be obtained, followed by oligonucleotide synthesis of portions of the sequence or, if appropriate, the entire sequence; thereafter, the portions or the entire synthetic sequence can be inserted into the appropriate locations within the vector. Those skilled in the art are credited with the ability to accomplish this task.

Our most preferred immunologically active chimeric anti-CD20 antibodies were derived from utilization of TCAE 8 vector which included murine variable regions derived from monoclonal antibody to CD20; this antibody (to be discussed in detail, *infra*), is referred to as "2B8." The complete sequence of the variable regions obtained from 2B8 in TCAE 8 ("anti-CD20 in TCAE 8") is set forth in Figure 3 (SEQ. ID. NO. 2).

The host cell line utilized for protein expression is most preferably of mammalian origin; those skilled in the art are credited with ability to preferentially determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXBII (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (a derivative of CVI with SV40 T antigen), R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/O (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-IcIBPT (bovine endothelial cells), RAJI (human lymphocyte) and 293 (human kidney). Host cell lines are typically available from commercial services, the American Tissue Culture Collection or from published literature.

Preferably the host cell line is either DG44 ("CHO") or SP2/O. See Urland, G. et al., "Effect of gamma rays and the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986), and Shulman, M. et al., "A better cell line for making hybridomas secreting specific antibodies." Nature 276:269 (1978), respectively. Most preferably, the host cell line is DG44. Transfection of the plasmid into the host cell can be accomplished by any technique available to those in the art. These include, but are not limited to, transfection (including electrophoresis and electroporation), cell fusion with enveloped DNA, microinjection, and infection with intact virus. See, Ridgway, A.A.G. "Mammalian Expression Vectors." Chapter 24.2, pp. 470-472 Vectors, Rodriguez and Denhardt, Eds. (Butterworths, Boston, MA 1988). Most preferably, plasmid introduction into the host is via electroporation.

F. EXAMPLES

15

20

30

35

45

55

The following examples are not intended, nor are they to be construed, as limiting the invention. The examples are intended to evidence: dose-imaging using a radiolabeled anti-CD20 antibody ("I2B8"); radiolabeled anti-CD20 antibody ("Y2B8"); and immunologically active, chimeric anti-CD20 antibody ("C2B8") derived utilizing a specific vector ("TCAE 8") and variable regions derived from murine anti-CD20 monoclonal antibody ("2B8").

I. RADIOLABELED ANTI-CD20 ANTIBODY 2B8

A. Anti-CD20 Monoclonal Antibody (Murine) Production ("2B8")

BALB/C mice were repeatedly immunized with the human lymphoblastoid cell line SB (*see*, Adams, R.A. *et al.*, "Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2." *Can Res 28*:1121-1125 (1968); this cell line is available from the American Tissue Culture Collection, Rockville, MD., under ATCC accession number ATCC CCL 120), with weekly injections over a period of 3-4 months. Mice evidencing high serum titers of anti-CD20 antibodies, as determined by inhibition of known CD20-specific antibodies (anti-CD20 antibodies utilized were Leu 16, Beckton Dickinson, San Jose, CA, Cat. No. 7670; and Bl, Coulter Corp., Hialeah, FL, Cat. No. 6602201) were identified; the spleens of such mice were then removed. Spleen cells were fused with the mouse myeloma SP2/0 in accordance with the protocol described in Einfeld, D.A. *et al.*, (1988) *EMBO 7*:711 (SP2/0 has ATCC accession no. ATCC CRL 8006).

Assays for CD20 specificity were accomplished by radioimmunoassay. Briefly, purified anti-CD20 Bl was radiolabeled with I¹²⁵ by the iodobead method as described in Valentine, M.A. *et al.*, (1989) *J. Biol. Chem. 264*:11282. (I¹²⁵ Sodium lodide, ICN, Irvine, CA, Cat. No. 28665H). Hybridomas were screened by co-incubation of 0.05 ml of media from each of the fusion wells together with 0.05 ml of I¹²⁵ labeled anti-CD20 Bl (10 ng) in 1% BSA, PBS (pH 7.4), and 0.5 ml of the same buffer containing 100,000 SB cells. After incubation for 1 hr at room temperature, the cells were harvested by transferring to 96 well titer plates (V&P Scientific, San Diego, CA), and washed thoroughly. Duplicate wells containing unlabeled anti-CD20 Bl and wells containing no inhibiting antibody were used as positive and negative controls, respectively. Wells containing greater than 50% inhibition were expanded and cloned. The antibody demonstrating the highest inhibition was derived from the cloned cell line designated herein as "2B8."

B. Preparation of 2B8-MX-DTPA Conjugate

i. MX-DTPA

Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid ("carbon-14 labeled MX-DTPA") was used as a chelating agent for conjugation of radiolabel to 2B8. Manipulations of MX-DTPA were conducted to maintain metal-free conditions, *ie* metal-free reagents were utilized and, when possible, polypropylene plastic containers (flasks, beakers, graduated cylinders, pipette tips) washed with Alconox and rinsed with Milli-Q water, were similarly utilized. MX-DTPA was obtained as a dry solid from Dr. Otto Gansow (National Institute of Health, Bethesda, MD) and stored desiccated at 4°C (protected from light), with stock solutions being prepared in Milli-Q water at a concentration of 2-5mM, with storage at -70°C. MX-DTPA was also obtained from Coulter Immunology (Hialeah, Florida) as the disodium salt in water and stored at -70°C.

ii. Preparation of 2B8

Purified 2B8 was prepared for conjugation with MX-DTPA by transferring the antibody into metal-free 50mM bicine-NaOff, pH 8.6, containing 150 mM NaCl, using repetitive buffer exchange with CENTRICON 30™ spin filters (30,000D, MWCO; Amicon). Generally, 50-200 µL of protein (10 mg/nl) was added to the filter unit, followed by 2 mL of bicine buffer. The filter was centrifuged at 4°C in a Sorval SS-34 rotor (6,000 rpm, 45 min.). Retentate volume was approximately 50-100 µL; this process was repeated twice using the same filter. Retentate was transferred to a polypropylene 1.5 mL screw cap tube, assayed for protein, diluted to 10.0 mg/mL and stored at 4°C until utilized; protein was similarly transferred into 50 mM sodium citrate, pH 5.5, containing 150 mM NaCl and 0.05% sodium azide, using the foregoing protocol.

iii. Conjugation of 2B8 with MX-DTPA

Conjugation of 2B8 with MX-DTPA was performed in polypropylene tubes at ambient temperature. Frozen MX-DTPA stock solutions were thawed immediately prior to use. 50-200 mL of protein at 10 mg/mL were reacted with MX-DTPA at a molar ratio of MX-DTPA-to-2B8 of 4:1. Reactions were initiated by adding the MX-DTPA stock solution and gently mixing; the conjugation was allowed to proceed overnight (14 to 20 hr), at ambient temperature. Unreacted MX-

DTPA was removed from the conjugate by dialysis or repetitive ultrafiltration, as described above in Example I.B.ii, into metal-free normal saline (0.9% w/v) containing 0.05% sodium azide. The protein concentration was adjusted to 10 mg/mL and stored at 4°C in a polypropylene tube until radiolabeled.

iv. Determination of MX-DTPA Incorporation

5

10

25

40

MX-DTPA incorporation was determined by scintillation, counting and comparing the value obtained with the purified conjugate to the specific activity of the carbon-[14]-labeled MX-DTPA. For certain studies, in which non-radio-active MX-DTPA (Coulter Immunology) was utilized, MX-DTPA incorporation was assessed by incubating the conjugate with an excess of a radioactive carrier solution of yttrium-[90] of known concentration and specific activity.

A stock solution of yttrium chloride of known concentration was prepared in metal-free 0.05 N HCl to which carrier-free yttrium-[90] (chloride salt) was added. An aliquot of this solution was analyzed by liquid scintillation counting to determine an accurate specific activity for this reagent. A volume of the yttrium chloride reagent equal to 3-times the number of mols of chelate expected to be attached to the antibody, (typically 2 mol/mol antibody), was added to a polypropylene tube, and the pH adjusted to 4.0-4.5 with 2 M sodium acetate. Conjugated antibody was subsequently added and the mixture incubated 15-30 min. at ambient temperature. The reaction was quenched by adding 20 mM EDTA to a final concentration of 1 mM and the pH of the solution adjusted to approximately pH 6 with 2M sodium acetate.

After a 5 min. incubation, the entire volume was purified by high-performance, size-exclusion chromatography (described *infra*). The eluted protein-containing fractions were combined, the protein concentration determined, and an aliquot assayed for radioactivity. The chelate incorporation was calculated using the specific activity of the yttrium-[90] chloride preparation and the protein concentration.

v. Immunoreactivity of 2B8-MX-DTPA

The immunoreactivity of conjugated 2B8 was assessed using whole-cell ELISA. Mid-log phase SB cells were harvested from culture by centrifugation and washed two times with 1X HBSS. Cells were diluted to 1-2 X 10^6 cells/mL in HBSS and aliquoted into 96-well polystyrene microtiter plates at 50,000-100,000 cells/well. The plates were dried under vacuum for 2 h. at 40-45°C to fix the cells to the plastic; plates were stored dry at -20°C until utilized. For assay, the plates were warmed to ambient temperature immediately before use, then blocked with 1X PBS, pH 7.2-7.4 containing 1% BSA (2 h). Samples for assay were diluted in 1X PBS/1% BSA, applied to plates and serially diluted (1:2) into the same buffer. After incubating plates for 1 h. at ambient temperature, the plates were washed three times with 1X PBS. Secondary antibody (goat anti-mouse IgG1-specific HRP conjugate $50~\mu$ L) was added to wells (1:1500 dilution in 1X PBS/1% BSA) and incubated 1 h. at ambient temperature. Plates were washed four times with 1X PBS followed by the addition of ABTS substrate solution (50 mM sodium citrate, pH 4.5 containing 0.01% ATBS and 0.001% H_2O_2). Plates were read at 405 nm after 15-30 min. incubation. Antigen-negative HSB cells were included in assays to monitor non-specific binding. Immunoreactivity of the conjugate was calculated by plotting the absorbance values vs. the respective dilution factor and comparing these to values obtained using native antibody (representing 100% immunoreactivity) tested on the same plate; several values on the linear portion of the titration profile were compared and a mean value determined (data not shown).

vi. Preparation of Indium-[111]-Labeled 2B8-MX-DTPA ("I2B8")

Conjugates were radiolabeled with carrier-free indium-[111]. An aliquot of isotope (0.1-2 mCi/mg antibody) in 0.05 M HCL was transferred to a polypropylene tube and approximately one-tenth volume of metal-free 2 M HCl added. After incubation for 5 min., metal-free 2 M sodium acetate was added to adjust the solution to pH 4.0-4.4. Approximately 0.5 mg of 2B8-MX-DTPA was added from a stock solution of 10.0 mg/mL DTPA in normal saline, or 50 mM sodium citrate/150 mM NaCl containing 0.05% sodium azide, and the solution gently mixed immediately. The pH solution was checked with pH paper to verify a value of 4.0-4.5 and the mixture incubated at ambient temperature for 15-30 min. Subsequently, the reaction was quenched by adding 20 mM EDTA to a final concentration of 1 mM and the reaction mixture was adjusted to approximately pH 6.0 using 2 M sodium acetate.

After a 5-10 min. incubation, uncomplexed radioisotope was removed by size-exclusion chromatography. The HPLC unit consisted of Waters Model 6000 or TosoHaas Model TSK-6110 solvent delivery system fitted, respectively, with a Waters U6K or Rheodyne 700 injection valve. Chromatographic separations were performed using a gel permeation column (BioRad SEC-250; 7.5 x 300 mm or comparable TosoHaas column) and a SEC-250 guard column (7.5 x 100 mm). The system was equipped with a fraction collector (Pharmacia Frac200) and a UV monitor fitted with a 280 nm filter (Pharmacia model UV-1). Samples were applied and eluted isocratically using 1X PBS, pH 7.4, at 1.0 mL/min flow rate. One-half milliliter fractions were collected in glass tubes and aliquots of these counted in a gamma counter. The lower and upper windows were set to 100 and 500 KeV respectively.

The radioincorporation was calculated by summing the radioactivity associated with the eluted protein peak and dividing this number by the total radioactivity eluted from the column; this value was then expressed as a percentage (data not shown). In some cases, the radioincorporation was determined using instant thin-layer chromatography ("ITLC"). Radiolabeled conjugate was diluted 1:10 or 1:20 in 1X PBS containing or 1X PBS/1 mM DTPA, then 1 μ L was spotted 1.5 cm from one end of a 1 x 5 cm strip of ITLC SG paper. The paper was developed by ascending chromatography using 10% ammonium acetate in methanol:water (1:1; ν / ν). The strip was dried, cut in half crosswise, and the radioactivity associated with each section determined by gamma counting. The radioactivity associated with the bottom half of the strip (protein-associated radioactivity) was expressed as a percentage of the total radioactivity, determined by summing the values for both top and bottom halves (data not shown).

Specific activities were determined by measuring the radioactivity of an appropriate aliquot of the radiolabeled conjugate. This value was corrected for the counter efficiency (typically 75%) and related to the protein concentration of the conjugate, previously determined by absorbance at 280 nm, and the resulting value expressed as mCi/mg protein.

For some experiments, 2B8-MX-DTPA was radiolabeled with indium [111] following a protocol similar to the one described above but without purification by HPLC; this was referred to as the "mix-and-shoot" protocol.

vii. Preparation of Yttrium-[90]-Labeled 2B8-MX-DTPA ("Y2B8")

The same protocol described for the preparation of I2B8 was followed for the preparation of the yttrium-[90]-labeled 2B8-MX-DTPA ("Y2B8") conjugate except that 2 ng HCl was not utilized; all preparations of yttrium-labeled conjugates were purified by size-exclusion chromatography as described above.

C. Non-Human Animal Studies.

10

15

20

25

35

55

i. Biodistribution of Radiolabeled 2B8-MX-DTPA

I2B8 was evaluated for tissue biodistribution in six-to-eight week old BALB/c mice. The radiolabeled conjugate was prepared using clinical-grade 2B8-MX-DTPA following the "mix and shoot" protocol described above. The specific activity of the conjugate was 2.3 mCi/mg and the conjugate was formulated in PBS, pH 7.4 containing 50mg/mL HSA. Mice were injected intravenously with 100 μ L of I2B8 (approximately 21 μ Ci) and groups of three mice were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours. After sacrifice, the tail, heart, lungs, liver, kidney, spleen, muscle, and femur were removed, washed and weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue subsequently determined. No attempt was made to discount the activity contribution represented by the blood associated with individual organs.

In a separate protocol, aliquots of 2B8-MX-DTPA incubated at 4°C and 30°C for 10 weeks were radiolabeled with indium-[111] to a specific activity of 2.1 mCi/mg for both preparations. These conjugates were then used in biodistribution studies in mice as described above.

For dosimetry determinations, 2B8-MX-DTPA was radiolabeled with indium[111] to a specific activity of 2.3 mCi/mg and approximately 1.1 μ Ci was injected into each of 20 BALB/c mice. Subsequently, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their organs removed and prepared for analysis. In addition, portions of the skin, muscle and bone were removed and processed for analysis; the urine and feces were also collected and analyzed for the 24-72 hour time points.

Using a similar approach, 2B8-MX-DTPA was also radiolabeled with yttrium-[90] and its biological distribution evaluated in BALB/c mice over a 72-hour time period. Following purification by HPLC size exclusion chromatography, four groups of five mice each were injected intravenously with approximately 1 μ Ci of clinically-formulated conjugate (specific activity:12.2 mCi/mg); groups were subsequently sacrificed at 1, 24, 48 and 72 hours and their organs and tissues analyzed as described above. Radioactivity associated with each tissue specimen was determined by measuring bremstrahlung energy with a gamma scintillation counter. Activity values were subsequently expressed as percent injected dose per gram tissue or percent injected dose per organ. While organs and other tissues were rinsed repeatedly to remove superficial blood, the organs were not perfused. Thus, organ activity values were not discounted for the activity contribution represented by internally associated blood.

ii. Tumor Localization of I2B8

The localization of radiolabeled 2B8-MX-DTPA was determined in athymic mice bearing Ramos B cell tumors. Six-to-eight week old athymic mice were injected subcutaneously (left-rear flank) with 0.1 mL of RPMI-1640 containing 1.2 X 10^7 Ramos tumor cells which had been previously adapted for growth in athymic mice. Tumors arose within two weeks and ranged in weight from 0.07 to 1.1 grams. Mice were injected intravenously with 100 μ L of indium-[111]-labeled 2B8-MX-DTPA (16.7 μ Ci) and groups of three mice were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours.

After sacrifice the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor were removed, washed, weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue determined.

iii. Biodistribution and Tumor Localization Studies with Radiolabeled 2B8-MX-DTPA

Following the preliminary biodistribution experiment described above (Example I.B.viii.a.), conjugated 2B8 was radiolabeled with indium-[111] to a specific activity of 2.3 mCi/mg and roughly 1.1 µCi was injected into each of twenty BALB/c mice to determine biodistribution of the radiolabeled material. Subsequentially, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their organs and a portion of the skin, muscle and bone were removed and processed for analysis. In addition, the urine and feces were collected and analyzed for the 24-72 hour time-points. The level of radioactivity in the blood dropped from 40.3% of the injected dose per gram at 1 hour to 18.9% at 72 hours (data not shown). Values for the heart, kidney, muscle and spleen remained in the range of 0.7-9.8% throughout the experiment. Levels of radioactivity found in the lungs decreased from 14.2% at 1 hour to 7.6% at 72 hours; similarly the respective liver injected-dose per gram values were 10.3% and 9.9%. These data were used in determining radiation absorbed dose estimates I2B8 described below.

The biodistribution of yttrium-[90]-labeled conjugate, having a specific activity of 12.2 mCi/mg antibody, was evaluated in BALB/c mice. Radioincorporations of >90% were obtained and the radiolabeled antibody was purified by HPLC. Tissue deposition of radioactivity was evaluated in the major organs, and the skin, muscle, bone, and urine and feces over 72 hours and expressed as percent injected dose/g tissue. Results (not shown) evidenced that while the levels of radioactivity associated with the blood dropped from approximately 39.2% injected dose per gram at 1 hour to roughly 15.4% after 72 hours the levels of radioactivity associated with tail, heart, kidney, muscle and spleen remained fairly constant at 10.2% or less throughout the course of the experiment. Importantly, the radioactivity associated with the bone ranged from 4.4% of the injected dose per gram bone at 1 hour to 3.2% at 72 hours. Taken together, these results suggest that little free yttrium was associated with the conjugate and that little free radiometal was released during the course of the study. These data were used in determining radiation absorbed dose estimates for Y2B8 described below.

For tumor localisation studies, 2B8-MX-DTPA was prepared and radiolabeled with 111 Indium to a specific activity of 2.7 mCi/mg. One hundred microliters of labeled conjugate (approximately 24 μ Ci) were subsequently injected into each of 12 athymic mice bearing Ramos B cell tumors. Tumors ranged in weight from 0.1 to 1.0 grams. At time points of 0, 24, 48, and 72 hours following injection, 50 μ L of blood was removed by retro-orbital puncture, the mice sacrificed by cervical dislocation, and the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor removed. After processing and weighing the tissues, the radioactivity associated with each tissue specimen was determined using a gamma counter and the values expressed as percent injected dose per gram.

The results (not shown) evidenced that the tumor concentrations of the ¹¹¹In-2B8-MX-DTPA increased steadily throughout the course of the experiment. Thirteen percent of the injected dose was accumulated in the tumor after 72 hours. The blood levels, by contrast, dropped during the experiment from over 30% at time zero to 13% at 72 hours. All other tissues (except muscle) contained between 1.3 and 6.0% of the injected dose per gram tissue by the end of the experiment; muscle tissue contained approximately 13% of the injected dose per gram.

40 D. Human Studies

5

i. 2B8 and 2B8-MX-DTPA: Immunohistology Studies with Human Tissues

The tissue reactivity of murine monoclonal antibody 2B8 was evaluated using a panel of 32 different human tissues fixed with acetone. Antibody 2B8 reacts with the anti-CD20 antigen which had a very restricted pattern of tissue distribution, being observed only in a subset of cells in lymphoid tissues including those of hematopoietic origin.

In the lymph node, immunoreactivity was observed in a population of mature cortical B-lymphocytes as well as proliferating cells in the germinal centers. Positive reactivity was also observed in the peripheral blood, B-cell areas of the tonsils, white pulp of the spleen, and with 40-70% of the medullary lymphocytes found in the thymus. Positive reactivity was also seen in the follicles of the lamina propria (Peyer's Patches) of the large intestines. Finally, aggregates or scattered lymphoid cells in the stroma of various organs, including the bladder, breast, cervix, esophagus, lung, parotid, prostate, small intestine, and stomach, were also positive with antibody 2B8 (data not shown).

All simple epithelial cells, as well as the stratified epithelia and epithelia of different organs, were found to be unreactive. Similarly, no reactivity was seen with neuroectodermal cells, including those in the brain, spinal cord and peripheral nerves. Mesenchymal elements, such as skeletal and smooth muscle cells, fibroblasts, endothelial cells, and polymorphonuclear inflammatory cells were also found to be negative (data not shown).

The tissue reactivity of the 2B8-MX-DTPA conjugate was evaluated using a panel of sixteen human tissues which had been fixed with acetone. As previously demonstrated with the native antibody (data not shown), the 2B8-MX-DTPA conjugate recognized the CD20 antigen which exhibited a highly restricted pattern of distribution, being found only on

a subset of cells of lymphoid origin. In the lymph node, immunoreactivity was observed in the B cell population. Strong reactivity was seen in the white pulp of the spleen and in the medullary lymphocytes of the thymus. Immunoreactivity was also observed in scattered lymphocytes in the bladder, heart, large intestines, liver, lung, and uterus, and was attributed to the presence of inflammatory cells present in these tissues. As with the native antibody, no reactivity was observed with neuroectodermal cells or with mesenchymal elements (data not shown).

- ii. Clinical Analysis of I2B8 (Imaging) and Y2B8 (Therapy)
- a. Phase I/II Clinical Trial Single Dose Therapy Study

A Phase I/II clinical analysis of I2B8 (imaging) followed by treatment with a single therapeutic dose of Y2B8 is currently being conducted. For the single-dose study, the following schema is being followed:

- 1. Peripheral Stem Cell (PSC) or Bone Marrow (BM) Harvest with Purging;
- 2. I2B8 Imaging;

10

15

20

25

30

40

50

55

- 3. Y2B8 Therapy (three Dose Levels); and
- 4. PSC or Autologous BM Transplantation (if necessary based upon absolute neutrophil count below 500/mm³ for three consecutive days or platelets below 20,000/mm³ with no evidence of marrow recovery on bone marrow examination).

The Dose Levels of Y2B8 are as follows:

Dose Level	Dose (mCi)
1.	20
2.	30
3.	40

Three patients are to be treated at each of the dose levels for determination of a Maximum Tolerated Dose ("MTD").

Imaging (Dosimetry) Studies are conducted as follows: each patient is involved in two *in vivo* biodistribution studies using I2B8. In the first study, 2mg of I2B8 (5mCi), is administered as an intravenous (i.v.) infusion over one hour; one week later 2B8 (ie unconjugated antibody) is administered by i.v. at a rate not to exceed 250mg/hr followed immediately by 2mg of I2B8 (5mCi) administered by i.v. over one hour. In both studies, immediately following the I2B8 infusion, each patient is imaged and imaging is repeated at time t = 14-18 hr (if indicated), t = 24 hr; t = 72 hr; and t = 96 hr (if indicated). Whole body average retention times for the indium [111] label are determined; such determinations are also made for recognizable organs or tumor lesions ("regions of interest").

The regions of interest are compared to the whole body concentrations of the label; based upon this comparison, an estimate of the localization and concentration of Y2B8 can be determined using standard protocols. If the estimated cumulative dose of Y2B8 is greater than eight (8) times the estimated whole body dose, or if the estimated cumulative dose for the liver exceeds 1500 cGy, no treatment with Y2B8 should occur.

If the imaging studies are acceptible, either 0.0 or 1.0mg/kg patient body weight of 2B8 is administered by i.v. infusion at a rate not to exceed 250mg/h. This is followed by administration of Y2B8 (10,20 or 40mCi) at an i.v. infusion rate of 20mCi/hr.

b. Phase I/II Clinical Trial: Multiple Dose Therapy Study

A Phase I/II clinical analysis of of Y2B8 is currently being conducted. For the multiple-dose study, the following schema is being followed:

- 1. PSC or BM Harvest;
- 2. I2B8 Imaging;
- 3. Y2B8 Therapy (three Dose Levels) for four doses or a total cumulative dose of 80mCi; and
- 4. PSC or Autologous BM Transplantation (based upon decision of medical practitioner).

The Dose Levels of Y2B8 are as follows:

5

10

15

25

30

35

Dose Level	Dose (mCi)
1.	10
2.	15
3.	20

_

Three patients are to be treated at each of the dose levels for determination of an MTD.

Imaging (Dosimetry) Studies are conducted as follows: A preferred imaging dose for the unlabeled antibody (ie 2B8) will be determined with the first two patients. The first two patients will receive 100mg of unlabeled 2B8 in 250cc of normal saline over 4 hrs followed by 0.5mCi of I2B8 -- blood will be sampled for biodistribution data at times t = 0, t = 10min., t = 120 min., t = 24 hr, and t = 48 hr. Patients will be scanned with multiple regional gamma camera images at times t = 2 hr, t = 24 hr and t = 48 hr. After scanning at t = 48 hr, the patients will receive 250mg of 2B8 as described, followed by 4.5mCi of I2B8 -- blood and scanning will then follow as described. If 100mg of 2B8 produces superior imaging, then the next two patients will receive 50mg of 2B8 as described, followed by 0.5mCi of I2B8 followed 48 hrs later by 100mg 2B8 and then with 4.5mCi of I2B8. If 250mg of 2B8 produces superior imaging, then the next two patients will receive 250mg of 2B8 as described, followed by 0.5mCi of I2B8 followed 48 hrs later with 500mg 2B8 and then with 4.5mCi of I2B8. Subsequent patients will be treated with the lowest amount of 2B8 that provides optimal imaging. Optimal imaging will be defined by: (1) best effective imaging with the slowest disappearance of antibody; (2) best distribution minimizing compartmentalization in a single organ; and (3) best subjective resolution of the lesion (tumor/background comparison).

For the first four patients, the first therapeutic dose of Y2B8 will begin 14 days after the last dose of I2B8; for subsequent patients, the first therapeutic dose of Y2B8 will begin between two to seven days after the I2B8.

Prior to treatment with Y2B8, for the patients other than the first four, 2B8 will be administered as described, followed by i.v. infusion of Y2B8 over 5-10 min. Blood will be sampled for biodistribution at times t = 0, t = 10min., t = 120 min., t = 24 hr and t = 48 hr. Patients will receive repetitive doses of Y2B8 (the same dose administered as with the first dose) approximately every six to eight weeks for a maximum of four doses, or total cumulative dose of 80mCi. It is most preferred that patients not receive a subsequent dose of Y2B8 until the patients' WBC is greater than/equal to 3,000 and AGC is greater than/equal to 100,000.

Following completion of the three-dose level study, an MTD will be defined. Additional patients will then be enrolled in the study and these will receive the MTD.

II. CHIMERIC ANTI-CD20 ANTIBODY PRODUCTION ("C2B8")

A. Construction of Chimeric Anti-CD20 Immunoglobulin DNA Expression Vector

40

RNA was isolated from the 2B8 mouse hybridoma cell (as described in Chomczynki, P. et al., "Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction." Anal. Biochem. 162:156-159(1987)). and cDNA was prepared therefrom. The mouse immunoglobulin light chain variable region DNA was isolated from the cDNA by polymerase chain reaction using a set of DNA primers with homology to mouse light chain signal sequences at the 5' end and mouse light chain J region at the 3' end. Primer sequences were as follows:

```
1. V_L Sense (SEQ. ID. NO. 3)
```

5' ATC AC AGATCT CTC ACC ATG GAT TTT CAG GTG CAG

ATT ATC AGC TTC 3'

(The underlined portion is a Bgl II site; the above-lined portion is the start codon.)

2. V_I Antisense (SEQ. ID. NO. 4)

5' TGC AGC ATC CGTACG TTT GAT TTC CAG CTT 3'

(The underlined portion is a Bsi WI site.)

55

50

See, Figures 1 and 2 for the corresponding Bgl II and Bsi WI sites in TCAE 8, and Figure 3 for the corresponding sites in anti-CD20 in TCAE 8.

These resulting DNA fragment was cloned directly into the TCAE 8 vector in front of the human kappa light chain constant domain and sequenced. The determined DNA sequence for the murine variable region light chain is set forth

in Figure 4 (SEQ. ID. NO. 5); see also Figure 3, nucleotides 978 through 1362. Figure 4 further provides the amino acid sequence from this murine variable region, and the CDR and framework regions. The mouse light chain variable region from 2B8 is in the mouse kappa VI family. See, Kabat, supra.

The mouse heavy chain variable region was similarly isolated and cloned in front of the human IgGI constant domains. Primers were as follows:

 V_H Sense (SEQ. ID. NO. 6)
 GCG GCT CCC <u>ACGCGT</u> GTC CTG TCC CAG 3' (The underlined portion is an Mlu I site.)

2. V_H Antisense (SEQ. ID. NO. 7) 5' GG(G/C) TGT TGT <u>GCTAGC</u> TG(A/C) (A/G)GA GAC (G/A)GT GA 3' (The underlined portion is an Nhe I site.)

15

20

5

10

See, Figures 1 and 2 for corresponding Mlu I and Nhe I sites in TCAE 8, and Figure 3 for corresponding sites in anti-CD20 in TCAE 8.

The sequence for this mouse heavy chain is set forth in Figure 5 (SEQ. ID. NO. 8); see also Figure 3, nucleotide 2401 through 2820. Figure 5 also provides the amino acid sequence from this murine variable region, and the CDR and framework regions. The mouse heavy chain variable region from 2B8 is in the mouse VH 2B family. See, Kabat, supra.

B. Creation of Chimeric Anti-CD20 Producing CHO and SP2/0 Transfectomas

Chinese hamster ovary ("CHO") cells DG44 were grown in SSFM II minus hypoxanthine and thymidine media (Gibco, Grand Island, NY, Form No. 91-0456PK); SP2/0 mouse myeloma cells were grown in Dulbecco's Modified Eagles Medium media ("DMEM") (Irvine Scientific, Santa Ana, Ca., Cat. No. 9024) with 5% fetal bovine serum and 20 ml/L glutamine added. Four million cells were electroporated with either 25 μg CHO or 50 μg SP2/0 plasmid DNA that had been restricted with Not I using a BTX 600 electroporation system (BTX, San Diego, CA) in 0.4 ml disposable cuvettes. Conditions were either 210 volts for CHO or 180 volts for SP2/0, 400 microfaradays, 13 ohms. Each electroporation was plated into six 96 well dishes (about 7,000 cells/well). Dishes were fed with media containing G418 (GENETICIN, Gibco, Cat. No. 860-1811) at 400 μg/ml active compound for CHO (media further included 50 μM hypoxanthine and 8 μM thymidine) or 800 μg/ml for SP2/0, two days following electroporation and thereafter 2 or 3 days until colonies arose. Supernatant from colonies was assayed for the presence of chimeric immunoglobulin via an ELISA specific for human antibody. Colonies producing the highest amount of immunoglobulin were expanded and plated into 96 well plates containing media plus methotrexate (25 nM for SP2/0 and 5nM for CHO) and fed every two or three days. Supernatants were assayed as above and colonies producing the highest amount of immunoglobulin were examined. Chimeric anti-CD20 antibody was purified from supernatant using protein A affinity chromatography.

Purified chimeric anti-CD20 was analyzed by electrophoresis in polyacrylamide gels and estimated to be greater than about 95% pure. Affinity and specificity of the chimeric antibody was determined based upon 2B8. Chimeric anti-CD20 antibody tested in direct and competitive binding assays, when compared to murine anti-CD20 monoclonal antibody 2B8, evidenced comparable affinity and specificity on a number of CD20 positive B cells lines (data not presented). The apparent affinity constant ("Kap") of the chimeric antibody was determined by direct binding of 1¹²⁵ radiolabeled chimeric anti-CD20 and compared to radiolabeled 2B8 by Scatchard plot; estimated Kap for CHO produced chimeric anti-CD20 was 5.2 x 10⁻⁹ M and for SP2/0 produced antibody, 7.4x10⁻⁹M. The estimated Kap for 2B8 was 3.5 x 10⁻⁹ M. Direct competition by radioimmunoassay was utilized to confirm both the specificity and retention of immunoreactivity of the chimeric antibody by comparing its ability to effectively compete with 2B8. Substantially equivalent amounts of chimeric anti-CD20 and 2B8 antibodies were required to produce 50% inhibition of binding to CD20 antigens on B cells (data not presented), *ie* there was a minimal loss of inhibiting activity of the anti-CD20 antibodies, presumably due to chimerization.

The results of Example II.B indicate, *inter alia*, that chimeric anti-CD20 antibodies were generated from CHO and SP2/0 transfectomas using the TCAE 8 vectors, and these chimeric antibodies had substantially the same specificity and binding capability as murine anti-CD20 monoclonal antibody 2B8.

C. <u>Determination of Immunological Activity of Chimeric Anti-CD20 Antibodies</u>

55

50

i. Human C1q Analysis

Chimeric anti-CD20 antibodies produced by both CHO and SP2/0 cell lines were evaluated for human C1q binding in a flow cytometry assay using fluorescein labeled C1q (C1q was obtained from Quidel, Mira Mesa, CA, Prod. No. A400

and FITC label from Sigma, St. Louis MO, Prod. No. F-7250; FITC. Labeling of C1q was accomplished in accordance with the protocol described in *Selected Methods In Cellular Immunology*, Michell & Shiigi, Ed. (W.H. Freeman & Co., San Francisco, CA, 1980, p. 292). Analytical results were derived using a Becton Dickinson FACScan™ flow cytometer (fluorescein measured over a range of 515-545 nm). Equivalent amounts of chimeric anti-CD20 antibody, human IgG1,K myeloma protein (Binding Site, San Diego, Ca, Prod. No. BP078), and 2B8 were incubated with an equivalent number of CD20-positive SB cells, followed by a wash step with FACS buffer (.2% BSA in PBS, pH 7.4, .02% sodium azide) to remove unattached antibody, followed by incubation with FITC labeled C1q. Following a 30-60 min. incubation, cells were again washed. The three conditions, including FITC-labeled C1q as a control, were analyzed on the FACScan™ following manufacturing instructions. Results are presented in Figure 6.

As the results of Figure 6 evidence, a significant increase in fluorescence was observed only for the chimeric anti-CD20 antibody condition; *ie* only SB cells with adherent chimeric anti-CD20 antibody were C1q positive, while the other conditions produced the same pattern as the control.

ii. Complement Dependent Cell Lyses

10

15

Chimeric anti-CD20 antibodies were analyzed for their ability to lyse lymphoma cell lines in the presence of human serum (complement source). CD20 positive SB cells were labeled with 51 Cr by admixing 100μ Ci of 51 Cr with $1x10^6$ SB cells for 1 hr at 37° C; labeled SB cells were then incubated in the presence of equivalent amounts of human complement and equivalent amounts (0-50 μ g/ml) of either chimeric anti-CD20 antibodies or 2B8 for 4 hrsat 37° C (see, Brunner, K.T. et al., "Quantitative assay of the lytic action of immune lymphoid cells on 51 Cr-labeled allogeneic target cells in vitro." Immunology 14:181-189 (1968). Results are presented in Figure 7.

The results of Figure 7 indicate, *inter alia*, that chimeric anti-CD20 antibodies produced significant lysis (49%) under these conditions.

iii. Antibody Dependent Cellular Cytotoxicity Effector Assay

For this study, CD20 positive cells (SB) and CD20 negative cells (T cell leukemia line HSB; see, Adams, Richard, "Formal Discussion," Can. Res. 27:2479-2482(1967); ATCC deposit no. ATCC CCL 120.1) were utilized; both were labeled with 51 Cr. Analysis was conducted following the protocol described in Brunner, K.T. et al., "Quantitative assay of the lytic action of immune lymphoid cells on 51 Cr-labeled allogeneic target cells in vitro; inhibition by isoantibody and drugs." Immunology 14:181-189(1968); a substantial chimeric anti-CD20 antibody dependent cell mediated lysis of CD20 positive SB target cells (51 Cr-labeled) at the end of a 4 hr, 37°C incubation, was observed and this effect was observed for both CHO and SP2/0 produced antibody (effector cells were human peripheral lymphocytes; ratio of effector cells:target was 100:1). Efficient lysis of target cells was obtained at $3.9 \,\mu$ g/ml. In contrast, under the same conditions, the murine anti-CD20 monoclonal antibody 2B8 had a statistically insignificant effect, and CD20 negative HSB cells were not lysed. Results are presented in Figure 8.

The results of Example II indicate, inter alia, that the chimeric anti-CD20 antibodies of Example I were immunologically active.

(i) III. DEPLETION OF B CELLS IN VIVO USING CHIMERIC ANTI-CD20

A. Non-Human Primate Study

Three separate non-human primate studies were conducted. For convenience, these are referred to herein as "Chimeric Anti-CD20: CHO & SP2/0;" "Chimeric Anti-CD20: CHO;" and "High Dosage Chimeric Anti-CD20." Conditions were as follows:

Chimeric Anti-CD20: CHO & SP2/0

Six cynomolgus monkeys ranging in weight from 4.5 to 7 kilograms (White Sands Research Center, Alamogordo, NM) were divided into three groups of two monkeys each. Both animals of each group received the same dose of immunologically active chimeric anti-CD20 antibody. One animal in each group received purified antibody produced by the CHO transfectoma; the other received antibody produced by the SP2/0 transfectoma. The three groups received antibody dosages corresponding to 0.1 mg/kg, 0.4 mg/kg, and 1.6 mg/kg each day for four (4) consecutive days. The chimeric immunologically active anti-CD20 antibody, which was admixed with sterile saline, was administered by intravenous infusion; blood samples were drawn prior to each infusion. Additional blood samples were drawn beginning 24 hrs after the last injection (T=O) and thereafter on days 1, 3, 7, 14 and 28; blood samples were also taken thereafter at biweekly intervals until completion of the study at day 90.

Approximately 5 ml of whole blood from each animal was centrifuged at 2000 RPM for 5 min. Plasma was removed for assay of soluble chimeric anti-CD20 antibody levels. The pellet (containing peripheral blood leukocytes and red blood cells) was resuspended in fetal calf serum for fluorescent-labeled antibody analysis (see, "Fluorescent Antibody Labeling of Lymphoid Cell Population," infra.).

Chimeric Anti-CD20: CHO

Six cynomolgus monkeys ranging in weight from 4 to 6 kilograms (White Sands) were divided into three groups of two monkeys each. All animals were injected with immunologically active chimeric anti-CD20 antibodies produced from the CHO transfectoma (in sterile saline). The three groups were separated as follows: subgroup 1 received daily intravenous injections of 0.01 mg/kg of the antibody over a four (4) day period; subgroup 2 received daily intravenous injections of 0.4 mg/kg of the antibody over a four (4) day period; subgroup 3 received a single intravenous injection of 6.4 mg/kg of the antibody. For all three subgroups, a blood sample was obtained prior to initiation of treatment; additionally, blood samples were also drawn at T=0, 1, 3, 7, 14 and 28 days following the last injection, as described above, and these samples were processed for fluorescent labeled antibody analysis (see, "Fluorescent Antibody Labeling," infra.). In addition to peripheral blood B cell quantitation, lymph node biopsies were taken at days 7, 14 and 28 following the last injection, and a single cell preparation stained for quantitation of lymphocyte populations by flow cytometry.

High Dosage Chimeric Anti-CD20

20

30

35

45

5

10

Two cynomolgus monkeys (White Sands) were infused with 16.8 mg/kg of the immunologically active chimeric anti-CD20 antibodies from the CHO transfectomas (in sterile saline) weekly over a period of four consecutive weeks. At the conclusion of the treatment, both animals were anesthetized for removal of bone marrow; lymph node biopsies were also taken. Both sets of tissue were stained for the presence of B lymphocytes using Leu 16 by flow cytometry following the protocol described in Ling, N.R. et al., "B-cell and plasma cell antigens." Leucocyte Typing III White Cell Differentiations Antigens, A.J. McMichael, Ed. (Oxford University Press, Oxford UK, 1987), p. 302.

Fluorescent Antibody Labeling of Lymphoid Cell Population

After removal of plasma, leukocytes were washed twice with Hanks Balanced Salt Solution ("HBSS") and resuspended in a plasma equivalent volume of fetal bovine serum (heat inactivated at 56°C for 30 min.). A 0.1 ml volume of the cell preparation was distributed to each of six (6), 15 ml conical centrifuge tubes Fluorescein labeled monoclonal antibodies with specificity for the human lymphocyte surface markers CD2 (AMAC, Westbrook, ME), CD20 (Becton Dickinson) and human IgM (Binding Site, San Diego, CA) were added to 3 of the tubes for identifying T and B lymphocyte populations. All reagents had previously tested positive to the corresponding monkey lymphocyte antigens. Chimeric anti-CD20 antibody bound to monkey B cell surface CD20 was measured in the fourth tube using polyclonal goat antihuman IgG coupled with phycoerythrin (AMAC). This reagent was pre-adsorbed on a monkey Ig-sepharose column to prevent cross-reactivity to monkey lg, thus allowing specific detection and quantitation of chimeric anti-CD20 antibody bound to cells. A fifth tube included both anti-IgM and anti-human IgG reagents for double stained B cell population. A sixth sample was included with no reagents for determination of autofluorescence. Cells were incubated with fluorescent antibodies for 30 min., washed and fixed with 0.5 ml of fixation buffer (0.15 M NaCl, 1% paraformaldehyde, pH7.4) and analyzed on a Becton Dickinson FACScan™ instrument. Lymphocyte populations were initially identified by forward versus right angle light scatter in a dot-plot bitmap with unlabeled leucocytes. The total lymphocyte population was then isolated by gating out all other events. Subsequent fluorescence measurements reflected only gated lymphocyte specific events.

Depletion of Peripheral Blood B Lymphocytes

No observable difference could be ascertained between the efficacy of CHO and SP2/0 produced antibodies in depleting B cells *in vivo*, although a slight increase in B cell recovery beginning after day 7 for monkeys injected with chimeric anti-CD20 antibodies derived from CHO transfectomas at dosage levels 1.6 mg/kg and 6.4 mg/kg was observed and for the monkey injected with SP2/0 producing antibody at the 0.4 mg/kg dose level. Figures 9A, B and C provide the results derived from the chimeric anti-CD20:CHO & SP2/0 study, with Figure 9A directed to the 0.4 mg/kg dose level; Figure 9B directed to the 1.6 mg/kg dose level; and Figure 9C directed to the 6.4 mg/kg dose level.

As is evident from Figure 9, there was a dramatic decrease (>95%) in peripheral B cell levels after the therapeutic treatment across all tested dose ranges, and these levels were maintained up to seven (7) days post infusion; after this period, B cell recovery began, and, the time of recovery initiation was independent of dosage levels.

In the Chimeric Anti-CD20:CHO study, a 10-fold lower antibody dosage concentration (0.01 mg/kg) over a period of four daily injections (0.04 mg/kg total) was utilized. Figure 10 provides the results of this study. This dosage depleted

the peripheral blood B cell population to approximately 50% of normal levels estimated with either the anti-surface IgM or the Leu 16 antibody. The results also indicate that saturation of the CD20 antigen on the B lymphocyte population was not achieved with immunologically active chimeric anti-CD20 antibody at this dose concentration over this period of time for non-human primates; B lymphocytes coated with the antibody were detected in the blood samples during the initial three days following therapeutic treatment. However, by day 7, antibody coated cells were undetectable.

Table I summarizes the results of single and multiple doses of immunologically active chimeric anti-CD20 antibody on the peripheral blood populations; single dose condition was 6.4 mg/kg; multiple dose condition was 0.4 mg/kg over four (4) consecutive days (these results wore derived from the monkeys described above).

TABLE I PERIPHERAL BLOOD POPULATION FROM C2B8 PRIMATE STUDY

5	PERIP	HERAL BLOOD PO	JPULATION FROM	CZD8 PRIM	ALESTUDI
5	Monkey	<u>Dose</u>	Day	CD2	Anti-Hu IgG
10	A	0.4 mg/kg (4 doses)	Prebleed 0 7 21 28	81.5 86.5 85.5 93.3 85.5	0.2 0.0 -
15	В	0.4 mg/kg (4 doses)	Prebleed 0 7 21 28	81.7 94.6 92.2 84.9 84.1	0.1 0.1 -
20	С	6.4 mg/kg (1 dose)	Prebleed 7 21 28	77.7 85.7 86.7 76.7	0.0 0.1 -
25	D	6.4 mg/kg (1 dose)	Prebleed 7 21 28	85.7 94.7 85.2 85.9	0.1 0.1 -
30	Monkey	Anti-Hu IgG+ <u>Anti-Hu IgM*</u>	<u>Leu-16</u>	% B Cell De	pletion
35	A	0.3 0.1 -	9.4 0.0 1.2 2.1 4.1	0 97 99 78 66	
40	В	0.2 0.1	14.8 0.1 0.1 6.9 8.7	0 99 99 53 41	
45	С	0.2 0.1 -	17.0 0.0 14.7 8.1	0 99 15 62	٠
50	D	0.1 0.2 -	14.4 0.0 9.2 6.7	0 99 4 6 53	

*Double staining population which indicates extent of chimeric anti-CD20 coated B cells.

The data summarized in Table I indicates that depletion of B cells in peripheral blood under conditions of antibody excess occurred rapidly and effectively, regardless of single or multiple dosage levels. Additionally, depletion was observed for at least seven (7) days following the last injection, with partial B cell recovery observed by day 21.

Table II summarizes the effect of immunologically active, chimeric anti-CD20 antibodies on cell populations of lymph nodes using the treatment regimen of Table I (4 daily doses of 0.4 mg/kg; 1 dose of 6.4 mg/kg); comparative values for normal lymph nodes (control monkey, axillary and inguinal) and normal bone marrow (two monkeys) are also provided.

TABLE II CELL POPULATIONS OF LYMPH NODES

5		0222	1010=1110110	01 211/11 11 11 01		
5	Monkey A	<u>Dose</u> 0.4 mg/kg (4 doses)	<u>Day</u> 7 14	<u>CD2</u> 66.9 76.9	Anti-Hu IgM - 19.6	[
		(4 doses)	28	61.6	19.7	
10	В	0.4 mg/kg	7	59.4	-	
		(4 doses)	14	83.2	9.9	
			2 8	84.1	15.7	
15	С	6.4 mg/kg	7	75.5	-	
		(1 dose)	14	74.1	17.9	
			28	66.9	23.1	
	D	6.4 mg/kg	7	83.8	-	
20		(1 dose)	14	74.1	17.9	
			2 8	84.1	12.8	
		Anti-Hu IgG +	TABLE II (c	continued)		
	Monkey	Anti-Hu IgM		% B Lympho	vte Depletion	
25	A	7.4	$\frac{1}{40.1}$		1	•
		0.8	22.6		44	
		-	26.0		36	
	В	29.9	52.2		0	
30		0.7	14.5		64	
		-	14.6		64	
	C	22.3	35.2		13	
		1.1	23.9		41	
35		•	21.4		47	
	D	12.5	19.7		51	
	D	0.2	8.7		78	
40		-	12.9		6 8	
40			TABLE II (d	continued)		
		CD0	Anti-Hu IgG+	A 45 TT T-N#		Lymphocyte
	Normal Lym	CD2	<u>Anti-Hu IgM</u>	<u>Anti-Hu IgM</u>	<u>Leu-16</u>	<u>Depletion</u>
45	Nodes	ıpıı				
	Control 1					
	Axillary	55.4	25.0	_	41.4	NA
	Inguinal	52.1	31.2	<u>~</u>	39.5	NA
50	Normal Bon	e				
	Marrow	07.0	10.0			374
	Control 2	65.3	19.0	-	11.4	NA
	Control 3	29 .8	28.0	-	16.6	NA

55

The results of Table II evidence effective depletion of B lymphocytes for both treatment regimens. Table II further indicates that for the non-human primates, complete saturation of the B cells in the lymphatic tissue with immunologically

active, chimeric anti-CD20 antibody was not achieved; additionally, antibody coated cells were observed seven (7) days after treatment, followed by a marked depletion of lymph node B cells, observed on day 14.

Based upon this data, the single High Dosage Chimeric Anti-CD20 study referenced above was conducted, principally with an eye toward pharmacology/toxicology determination. *Ie* this study was conducted to evaluate any toxicity associated with the administration of the chimeric antibody, as well as the efficacy of B cell depletion from peripheral blood lymph nodes and bone marrow. Additionally, because the data of Table II indicates that for that study, the majority of lymph node B cells were depleted between 7 and 14 days following treatment, a weekly dosing regimen might evidence more efficacious results. Table III summarizes the results of the High Dosage Chimeric Anti-CD20 study.

TABLE III

CELL POPULATIONS OF LYMPH NODES AND BONE MARROW Lymphocyte Populations (%)									
Monkey	CD2 CD20 ^a mlgM + anti-C2B8 ^b C2B8 ^c Day ^d								
Inguinal Ly	mph No	ode							
E	90.0	5.3	4.8	6.5	22				
F	91.0	6.3	5.6	6.3	22				
G	89.9	5.0	3.7	5.8	36				
Н	85.4	12.3	1.7	1.8	36				
Bone Mari	row								
E	46.7	4.3	2.6	2.8	22				
F	41.8	3.0	2.1	2.2	22				
G	35.3	8.0	1.4	1.4	36				
Н	25.6	4.4	4.3	4.4	36				

^aIndicates population stained with Leu 16.

Both animals evaluated at 22 days post treatment cessation contained less than 5% B cells, as compared to 40% in control lymph nodes (*see*, Table II, *supra*). Similarly, in the bone marrow of animals treated with chimeric anti-CD20 antibody, the levels of CD20 positive cells were less than 3% as compared to 11-15% in the normal animals (*see*, Table II, *supra*). In the animals evaluated at 36 days post treatment cessation, one of the animals (H) had approximately 12% B cells in the lymph node and 4.4% B cells in bone marrow, while the other (G) had approximately 5% B cells in the lymph node and 0.8% in the bone marrow--the data is indicative of significant B cell depletion.

The results of Example III.A indicate, *inter alia*, that low doses of immunologically active, chimeric anti-CD20 leads to long-term peripheral blood B cell depletion in primates. The data also indicates that significant depletion of B cell populations was achieved in peripheral lymph nodes and bone marrow when repetitive high doses of the antibody were administered. Continued follow-up on the test animals has indicated that even with such severe depletion of peripheral B lymphocytes during the first week of treatment, no adverse health effects have been observed. Furthermore, as recovery of B cell population was observed, a conclusion to be drawn is that the pluripotent stem cells of these primates were not adversely affected by the treatment.

B. Clinical Analysis of C2B8

5

10

15

20

25

30

35

40

55

i. Phase I/II Clinical Trial of C2B8: Single Dose Therapy Study

Fifteen patients having histologically documented relapsed B cell lymphoma have been treated with C2B8 in a Phase I/II Clinical Trial. Each patient received a single dose of C2B8 in a dose-escalating study; there were three patients

^bIndicates double staining population, positive for surface IgM cells and chimeric antibody coated cells.

^cIndicates total population staining for chimeric antibody including double staining surface IgM positive cells and single staining (surface IgM negative) cells.

^dDays after injection of final 16.8 mg/kg dose.

per dose: 10mg/m²; 50mg/m²; 100mg/m²; 250mg/m² and 500mg/m². Treatment was by i.v. infusion through an 0.22 micron in-line filter with C2B8 being diluted in a final volume of 250cc or a maximal concentration of 1mg/ml of normal saline. Initial rate was 50cc/hr for the first hour; if no toxicity was seen, dose rate was able to be escalated to a maximum of 200cc/hr.

Toxicity (as indicated by the clinician) ranged from "none", to "fever" to "moderate" (two patients) to "severe" (one patient); all patients completed the therapy treatment. Peripheral Blood Lymphocytes were analyzed to determine, *inter alia*, the impact of C2B8 on T-cells and B-cells. Consistently for all patients, Peripheral Blood B Lymphocytes were depleted after infusion with C2B8 and such depletion was maintained for in excess of two weeks.

One patient (receiving 100mg/^2 of C2B8) evidenced a Partial Response to the C2B8 treatment (reduction of greater than 50% in the sum of the products of the perpendicular diameters of all measurable indicator lesions lasting greater than four weeks, during which no new lesions may appear and no existing lesions may enlarge); at least one other patient (receiving 500mg/m^2) evidenced a Minor Response to the C2B8 treatment (reduction of less than 50% but at least 25% in the sum of the products of the two longest perpendicular diameters of all measurable indicator lesions). For presentational efficiency, results of the PBLs are set forth in Figure 14; data for the patient evidencing a PR is set forth in Figure 14A; for the patient evidencing an MR, data is set forth in Figure 14B. In Figure 14, the following are applicable: \blacksquare = Lymphocytes; \blacksquare = CD3+ cells (T cells); \blacktriangle = CD20+ cells; \spadesuit = CD19+ cells; Θ = Kappa; \spadesuit = lambda; and \spadesuit = C2B8. As evidenced, the B cell markers CD20 and CD19, Kappa and Lambda, were depleted for a period in excess of two weeks; while there was a slight, initial reduction in T-cell counts, these returned to an approximate base-line level in a relatively rapid time-frame.

ii. Phase I/II Clinical Trial of C2B8: Multiple Dose Therapy Study

Patients having histologically confirmed B cell lymphoma with measurable progressive disease are eligible for this study which is separated into two parts: in Phase I, consisting of a dose escalation to characterize dose limiting toxicities and determination of biologically active tolerated dose level, groups of three patients will receive weekly i.v. infusions of C2B8 for a total of four (4) separate infusions. Cumulative dose at each of the three levels will be as follows: 500mg/m² (125mg/m²/infusion); 1000mg/m² (250mg/m²/infusion); 1500mg/m² (375mg/m²/infusion. A biologically active tolerated dose is defined, and will be determined, as the lowest dose with both tolerable toxicity and adequate activity); in Phase II, additional patients will receive the biologically active tolerated dose with an emphasis on determining the activity of the four doses of C2B8.

IV. COMBINATION THERAPY: C2B8 AND Y2B8

5

20

50

A combination therapeutic approach using C2B8 and Y2B8 was investigated in a mouse xenographic model (nu/nu mice, female, approximately 10 weeks old) utilizing a B cell lymphoblastic tumor (Ramos tumor cells). For comparative purposes, additional mice were also treated with C2B8 and Y2B8.

Ramos tumor cells (ATCC, CRL 1596) were maintained in culture using RPMI-1640 supplemented with 10% fetal calf serum and glutamine at 37° C and 5% CO₂. Tumors were initiated in nine female nude mice approximately 7-10 weeks old by subcutaneous injection of 1.7 x 10^6 Ramos cells in a volume of 0.10ml (HBSS) using a 1cc syringe fitted with 25g needle. All animals were manipulated in a laminar flow hood and all cages, bedding, food and water were autoclaved. Tumor cells were passaged by excising tumors and passing these through a 40 mesh screen; cells were washed twice with 1X HBSS (50ml) by centrifugation (1300RPM), resuspended in IX HBSS to 10×10^6 cells/ml, and frozen at -70°C until used.

For the experimental conditions, cells from several frozen lots were thawed, pelleted by centrifugation (1300RPM) and washed twice with 1X HBSS. Cells were then resuspended to approximately 2.0×10^6 cells/ml. Approximately 9 to 12 mice were injected with 0.10ml of the cell suspension (s.c.) using a 1cc syringe fitted with a 25g needle; injections were made on the animal's left side, approximately mid-region. Tumors developed in approximately two weeks. Tumors were excised and processed as described above. Study mice were injected as described above with 1.67 x 10^6 cells in 0.10ml HBSS.

Based on preliminary dosing experiments, it was determined that 200mg of C2B8 and $100\mu\text{C}i$ of Y2B8 would be utilized for the study. Ninety female nu/nu mice (approximately 10 weeks old) were injected with the tumor cells. Approximately ten days later, 24 mice were assigned to four study groups (six mice/group) while attempting to maintain a comparable tumor size distribution in each group (average tumor size, expressed as a product of length x width of the tumor, was approximately 80mm^2). The following groups were treated as indicated via tail-vain injections using a $100\mu\text{I}$ Hamilton syringe fitted with a 25g needle:

- A. Normal Saline
- B. Y2B8 (100μCi)
- C. C2B8 (200µg); and

D. Y2B8 (100µCi) + C2B8 (200µg)

Groups tested with C2B8 were given a second C2B8 injection (200µg/mouse) seven days after the initial injection. Tumor measurements were made every two or three days using a caliper.

Preparation of treatment materials were in accordance with the following protocols:

A. Preparation of Y2B8

5

20

25

30

35

Yttrium-[90] chloride (6mCi) was transformed to a polypropylene tube and adjusted to pH 4.1-4.4 using metal free 2M sodium acetate. 2B8-MX-DTPA (0.3mg in normal saline; see above for preparation of 2B8-MX-DTPA) was added and gently mixed by vortexing. After 15 min. incubation, the reaction was quenched by adding 0.05 x volume 20mM EDTA and 0.05X volume 2M sodium acetate. Radioactivity concentration was determined by diluting 5.0µl of the reaction mixture in 2.5ml 1 x PBS containing 75mg/ml HSA and 1mM DTPA ("formulation buffer"); counting was accomplished by adding 10.0µl to 20ml of Ecolume™ scintillation cocktail. The remainder of the reactive mixture was added to 3.0ml formulation buffer, sterile filtered and stored at 2-8°C until used. Specific activity (14mCi/mg at time of injection) was calculated using the radioactivity concentration and the calculated protein concentration based upon the amount of antibody added to the reaction mixture. Protein-associated radioactivity was determined using instant thin-layer chromatography. Radioincorporation was 95%. Y2B8 was diluted in formulation buffer immediately before use and sterile-filtered (final radioactivity concentration was 1.0mCi/ml).

B. Preparation of C2B8

C2B8 was prepared as described above. C2B8 was provided as a sterile reagent in normal saline at 5.0mg/ml. Prior to injection, the C2B8 was diluted in normal saline to 2.0mg/ml and sterile filtered.

C. Results

Following treatment, tumor size was expressed as a product of length and width, and measurements were taken on the days indicated in Figure 11 (Y2B8 vs. Saline); Figure 12 (C2B8 vs. Saline); and Figure 13 (Y2B8 + C2B8 vs. Saline). Standard error was also determined.

As indicated in Figure 13, the combination of Y2B8 and C2B8 exhibited tumoricidal effects comparable to the effects evidenced by either Y2B8 or C2B8.

V. ALTERNATIVE THERAPY STRATEGIES

Alternative therapeutic strategies recognized in view of the foregoing examples are evident. One such strategy employs the use of a therapeutic dose of C2B8 followed within about one week with a combination of either 2B8 and radioabeled 2B8 (eg Y2B8); or 2B8, C2B8 and, eg Y2B8; or C2B8 and, eg Y2B8. An additional strategy is utilization of radiolabeled C2B8 -- such a strategy allows for utilization of the benefits of the immunologically active portion of C2B8 plus those benefits associated with a radiolabel. Preferred radiolabels include yttrium-90 given the larger circulating halflife of C2B8 versus the murine antibody 2B8. Because of the ability of C2B8 to deplete B-cells, and the benefits to be derived from the use of a radiolabel, a preferred alternative strategy is to treat the patient with C2B8 (either with a single dose or multiple doses) such that most, if not all, peripheral B cells have been depleted. This would then be followed with the use of radiolabeled 2B8; because of the depletion of peripheral B cells, the radiolabeled 2B8 stands an increased chance of targeting tumor cells. Iodine [131] labeled 2B8 is preferably utilized, given the types of results reported in the literature with this label (see Kaminski). An alternative preference involves the use of a radiolabeled 2B8 (or C2B8) first in an effort to increase the permeability of a tumor, followed by single or multiple treatments with C2B8; the intent of this strategy is to increase the chances of the C2B8 in getting both outside and inside the tumor mass. A further strategy involved the use of chemotherapeutic agenst in combination with C2B8. These strategies include so-called "staggered" treatments, ie, treatment with chemotherapeutic agent, followed by treatment with C2B8, followed by a repetition of this protocol. Alternatively, initial treatment with a single or multiple doses of C2B8, thereafter followed with chemotherapeutic treatement, is viable. Preferred chemotherapeutic agents include, but are not limited to: cyclophlsphamide; doxorubicin; vincristine; and prednisone, See Armitage, J.O. et al., Cancer 50:1695 (1982), incorporated herein by reference.

The foregoing alternative therapy strategies are not intended to be limiting, but rather are presented as being representative.

VI. DEPOSIT INFORMATION

Anti-CD20 in TCAE 8 (transformed in *E. coli* for purposes of deposit) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, 20852, under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure ("Budapest Treaty"). The microorganism was tested by the ATCC on November 9, 1992, and determined to be viable on that date. The ATCC has assigned this microorganism for the following ATCC deposit number: ATCC 69119 (anti-CD20 in TCAE 8). Hybridoma 2B8 was deposited with the ATCC on June 22, 1993 under the provisions of the Budapest Treaty. The viability of the culture was determined on June 25, 1993 and the ATCC has assigned this hybridoma the following ATCC deposit number: HB 11388.

G. SEQUENCE LISTING

5	(1)	GENE	RAL INFORMATION
10		(i)	APPLICANT: Darrell Anderson, Nabil Hanna, John Leonard, Roland Newman and Mitchell Reff and William H. Rastetter
15		(ii)	TITLE OF INVENTION: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA
20		(iii)	NUMBER OF SEQUENCES: 8
		(iv)	CORRESPONDING ADDRESS:
25			(A) ADDRESSEE: IDEC Pharmaceuticals Corporation (B) STREET: 11011 Torreyana Road (C) CITY: San Diego (D) STATE: California (E) COUNTRY: USA (F) ZIP: 92121
30		(v)	COMPUTER READABLE FORM:
<i>35</i>			 (A) MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb (B) COMPUTER: Macintosh (C) OPERATING SYSTEM: MS.DOS (D) SOFTWARE: Microsoft Word 5.0
		(vi	CURRENT APPLICATION DATA:
40			(A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION:
		(viii)	ATTORNEY/AGENT INFORMATION:
45			 (A) NAME: Burgoon, Richard P. Jr. (B) REGISTRATION NUMBER: 34,787 (C) REFERENCE/DOCKET NUMBER:
50		(ix)	TELECOMMUNICATION INFORMATION:
			(A) TELEPHONE: (619) 550-8500 (B) TELEFAX: (619) 550-8750

INFORMATION FOR SEQ ID NO: 1:

(2)

5	(i)	SEQUENCE	E CHARACT	ERISTICS:	,		
10		(B) TYPE (C) STRA	GTH: 8540 b c: nucleic act NDEDNES: DLOGY: circ	id 3: single			
	(ii)	MOLECULI	E TYPE: DN	IA (genomic)		
	(iii)	НҮРОТНЕТ	CICAL: yes				
15	(iv)	ANTI-SENS	E: no				
	(ix)	SEQUENCE	E DESCRIPT	TION: SEQ	ID NO: 1:		
20	GACGTCGCGG	CCGCTCTAGG	CCTCCAAAAA	AGCCTCCTCA	CTACTTCTGG	AATAGCTCAG	60
	AGGCCGAGGC	GGCCTCGGCC	TCTGCATAAA	ТАААААААТ	TAGTCAGCCA	TGCATGGGGC	120
	GGAGAATGGG	CGGAACTGGG	CGGAGTTAGG	GGCGGGATGG	GCGGAGTTAG	GGGCGGACT	180
25	ATGGTTGCTG	ACTAATTGAG	ATGCATGCTT	TGCATACTTC	TGCCTGCTGG	GGAGCCTGGG	240
	GACTTTCCAC	ACCTGGTTGC	TGACTAATTG	AGATGCATGC	TTTGCATACT	TCTGCCTGCT	300
	GGGGAGCCTG	GGGACTTTCC	ACACCCTAAC	TGACACACAT	TCCACAGAAT	TAATTCCCCT	360
30	AGTTATTAAT	AGTAATCAAT	TACGGGGTCA	TTAGTTCATA	GCCCATATAT	GGAGTTCCGC	420
	GTTACATAAC	TTACGGTAAA	TGGCCCGCCT	GGCTGACCGC	CCAACGACCC	CCGCCCATTG	480
	ACGTCAATAA	TGACGTATGT	TCCCATAGTA	ACGCCAATAG	GGACTTTCCA	TTGACGTCAA	540
35	TGGGTGGACT	ATTTACGGTA	AACTGCCCAC	TTGGCAGTAC	ATCAAGTGTA	TCATATGCCA	600
	AGTACGCCCC	CTATTGACGT	CAATGACGGT	AAATGGCCCG	CCTGGCATTA	TGCCCAGTAC	660
	ATGACCTTAT	GGGACTTTCC	TACTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	720
40	ATGGTGATGC	GGTTTTGGCA	GTACATCAAT	GGGCGTGGAT	AGCGGTTTGA	CTCACGGGGA	780
	TTTCCAAGTC	TCCACCCCAT	TGACGTCAAT	GGGAGTTTGT	TTTGGCACCA	AAATCAACGG	840
	GACTTTCCAA	AATGTCGTAA	CAACTCCGCC	CCATTGACGC	AAATGGGCGG	TAGGCGTGTA	900
45	CGGTGGGAGG	TCTATATAAG	CAGAGCTGGG	TACGTGAACC	GTCAGATCGC	CTGGAGACGC	960
	CATCACAGAT	CTCTCACCAT	GAGGGTCCCC	GCTCAGCTCC	TGGGGCTCCT	GCTGCTCTGG	1020
	CTCCCAGGTG	CACGATGTGA	TGGTACCAAG	GTGGAAATCA	AACGTACGGT	GGCTGCACCA	1080
50	TCTGTCTTCA	TCTTCCCGCC	ATCTGATGAG	CAGTTGAAAT	CTGGAACTGC	CTCTGTTGTG	1140
	TGCCTGCTGA	ATAACTTCTA	TCCCAGAGAG	GCCAAAGTAC	AGTGGAAGGT	GGATAACGCC	1200
	CTCCAATCGG	GTAACTCCCA	GGAGAGTGTC	ACAGAGCAGG	ACAGCAAGGA	CAGCACCTAC	1260

		AGCCTCAGCA	GCACCCTGAC	GCTGAGCAAA	GCAGACTACG	AGAAACACAA	AGTCTACGCC	1320
5		TGCGAAGTCA	CCCATCAGGG	CCTGAGCTCG	CCCGTCACAA	AGAGCTTCAA	CAGGGGAGAG	1380
		TGTTGAATTC	AGATCCGTTA	ACGGTTACCA	ACTACCTAGA	CTGGATTCGT	GACAACATGC	1440
		GGCCGTGATA	TCTACGTATG	ATCAGCCTCG	ACTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	1500
10)	GTTTGCCCCT	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	TGTCCTTTCC	1560
		TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	TCTGGGGGGT	1620
		GGGGTGGGGC	AGGACAGCAA	GGGGAGGAT	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	1680
4.6		GCGGTGGGCT	CTATGGAACC	AGCTGGGGCT	CGACAGCTAT	GCCAAGTACG	CCCCCTATTG	1740
15	1	ACGTCAATGA	CGGTAAATGG	CCCGCCTGGC	ATTATGCCCA	GTACATGACC	TTATGGGACT	1800
		TTCCTACTTG	GCAGTACATC	TACGTATTAG	TCATCGCTAT	TACCATGGTG	ATGCGGTTTT	1860
		GGCAGTACAT	CAATGGGCGT	GGATAGCGGT	TTGACTCACG	GGGATTTCCA	AGTCTCCACC	1920
20)	CCATTGACGT	CAATGGGAGT	TTGTTTTGGC	ACCAAAATCA	ACGGGACTTT	CCAAAATGTC	1980
		GTAACAACTC	CGCCCCATTG	ACGCAAATGG	GCGGTAGGCG	TGTACGGTGG	GAGGTCTATA	2040
		TAAGCAGAGC	TGGGTACGTC	CTCACATTCA	GTGATCAGCA	CTGAACACAG	ACCCGTCGAC	2100
25	ī	ATGGGTTGGA	GCCTCATCTT	GCTCTTCCTT	GTCGCTGTTG	CTACGCGTGT	CGCTAGCACC	2160
		AAGGCCCAT	CGGTCTTCCC	CCTGGCACCC	TCCTCCAAGA	GCACCTCTGG	GGGCACAGCG	2220
		GCCCTGGGCT	GCCTGGTCAA	GGACTACTTC	CCCGAACCGG	TGACGGTGTC	GTGGAACTCA	2280
30)	GGCGCCCTGA	CCAGCGGCGT	GCACACCTTC	CCGGCTGTCC	TACAGTCCTC	AGGACTCTAC	2340
		TCCCTCAGCA	GCGTGGTGAC	CGTGCCCTCC	AGCAGCTTGG	GCACCCAGAC	CTACATCTGC	2400
		AACGTGAATC	ACAAGCCCAG	CAACACCAAG	GTGGACAAGA	AAGCAGAGCC	CAAATCTTGT	2460
35	ī	GACAAAACTC	ACACATGCCC	ACCGTGCCCA	GCACCTGAAC	TCCTGGGGGG	ACCGTCAGTC	2520
		TTCCTCTTCC	CCCCAAAACC	CAAGGACACC	CTCATGATCT	CCCGGACCCC	TGAGGTCACA	2580
		TGCGTGGTGG	TGGACGTGAG	CCACGAAGAC	CCTGAGGTCA	AGTTCAACTG	GTACGTGGAC	2640
40)	GGCGTGGAGG	TGCATAATGC	CAAGACAAAG	CCGCGGGAGG	AGCAGTACAA	CAGCACGTAC	2700
		CGTGTGGTCA	GCGTCCTCAC	CGTCCTGCAC	CAGGACTGGC	TGAATGGCAA	GGAGTACAAG	2760
		TGCAAGGTCT	CCAACAAAGC	CCTCCCAGCC	CCCATCGAGA	AAACCATCTC	CAAAGCCAAA	2820
45	ī	GGGCAGCCCC	GAGAACCACA	GGTGTACACC	CTGCCCCCAT	CCCGGGATGA	GCTGACCAAG	2880
		AACCAGGTCA	GCCTGACCTG	CCTGGTCAAA	GGCTTCTATC	CCAGCGACAT	CGCCGTGGAG	2940
		TGGGAGAGCA	ATGGGCAGCC	GGAGAACAAC	TACAAGACCA	CGCCTCCCGT	GCTGGACTCC	3000
50)	GACGGCTCCT	TCTTCCTCTA	CAGCAAGCTC	ACCG'IGGACA	AGAGCAGGTG	GCAGCAGGGG	3060
		AACGTCTTCT	CATGCTCCGT	GATGCATGAG	GCTCTGCACA	ACCACTACAC	GCAGAAGAGC	3120
		CTCTCCCTGT	CTCCGGGTAA	ATGAGGATCC	GTTAACGGTT	ACCAACTACC	TAGACTGGAT	3180

		TCGTGACAAC	ATGCGGCCGT	GATATCTACG	TATGATCAGC	CTCGACTGTG	CCTTCTAGTT	3240
5	ī	GCCAGCCATC	TGTTGTTTGC	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	3300
		CCACTGTCCT	TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3360
		CTATTCTGGG	GGGTGGGGTG	GGGCAGGACA	GCAAGGGGGA	GGATTGGGAA	GACAATACCA	3420
1	0	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	AACCAGCTGG	GGCTCGACAG	CGCTGGATCT	3480
		CCCGATCCCC	AGCTTTGCTT	CTCAATTTCT	TATTTGCATA	ATGAGAAAAA	AAGGAAAATT	3540
		AATTTTAACA	CCAATTCAGT	AGTTGATTGA	GCAAATGCGT	TGCCAAAAAG	GATGCTTTAG	3600
1	5	AGACAGTGTT	CTCTGCACAG	ATAAGGACAA	ACATTATTCA	GAGGGAGTAC	CCAGAGCTGA	3660
		GACTCCTAAG	CCAGTGAGTG	GCACAGCATT	CTAGGGAGAA	ATATGCTTGT	CATCACCGAA	3720
		GCCTGATTCC	GTAGAGCCAC	ACCTTGGTAA	GGGCCAATCT	GCTCACACAG	GATAGAGAGG	3780
2	o o	GCAGGAGCCA	GGGCAGAGCA	TATAAGGTGA	GGTAGGATCA	GTTGCTCCTC	ACATTTGCTT	3840
		CTGACATAGT	TGTGTTGGGA	GCTTGGATAG	CTTGGACAGC	TCAGGGCTGC	GATTTCGCGC	3900
		CAAACTTGAC	GGCAATCCTA	GCGTGAAGGC	TGGTAGGATT	TTATCCCCGC	TGCCATCATG	3960
2	25	GTTCGACCAT	TGAACTGCAT	CGTCGCCGTG	TCCCAAAATA	TGGGGATTGG	CAAGAACGGA	4020
		GACCTACCCT	GGCCTCCGCT	CAGGAACGAG	TTCAAGTACT	TCCAAAGAAT	GACCACAACC	4080
		TCTTCAGTGG	AAGGTAAACA	GAATCTGGTG	ATTATGGGTA	GGAAAACCTG	GTTCTCCATT	4140
3	0	CCTGAGAAGA	ATCGACCTTT	AAAGGACAGA	ATTAATATAG	TTCTCAGTAG	AGAACTCAAA	4200
		GAACCACCAC	GAGGAGCTCA	TTTTCTTGCC	AAAAGTTTGG	ATGATGCCTT	AAGACTTATT	4260
		GAACAACCGG	AATTGGCAAG	TAAAGTAGAC	ATGGTTTGGA	TAGTCGGAGG	CAGTTCTGTT	4320
3	5	TACCAGGAAG	CCATGAATCA	ACCAGGCCAC	CTTAGACTCT	TTGTGACAAG	GATCATGCAG	4380
		GAATTTGAAA	GTGACACGTT	TTTCCCAGAA	ATTGATTTGG	GGAAATATAA	ACTTCTCCCA	4440
		GAATACCCAG	GCGTCCTCTC	TGAGGTCCAG	GAGGAAAAAG	GCATCAAGTA	TAAGTTTGAA	4500
4	0	GTCTACGAGA	AGAAAGACTA	ACAGGAAGAT	GCTTTCAAGT	TCTCTGCTCC	CCTCCTAAAG	4560
		CTATGCATTT	TTATAAGACC	ATGGGACTTT	TGCTGGCTTT	AGATCAGCCT	CGACTGTGCC	4620
		TTCTAGTTGC	CAGCCATCTG	TTGTTTGCCC	CTCCCCCGTG	CCTTCCTTGA	CCCTGGAAGG	4680
4	5	TGCCACTCCC	ACTGTCCTTT	ССТААТАААА	TGAGGAAATT	GCATCGCATT	GTCTGAGTAG	4740
		GTGTCATTCT	ATTCTGGGGG	GTGGGGTGGG	GCAGGACAGC	AAGGGGGAGG	ATTGGGAAGA	4800
		CAATAGCAGG	CATGCTGGGG	ATGCGGTGGG	CTCTATGGAA	CCAGCTGGGG	CTCGAGCTAC	4860
5	ro	TAGCTTTGCT	TCTCAATTTC	TTATTTGCAT	AATGAGAAAA	AAAGGAAAAT	TAATTTTAAC	4920
		ACCAATTCAG	TAGTTGATTG	AGCAAATGCG	TTGCCAAAAA	GGATGCTTTA	GAGACAGTGT	4980
		TCTCTGCACA	GATAAGGACA	AACATTATTC	AGAGGGAGTA	CCCAGAGCTG	AGACTCCTAA	5040

	GCCAGTGAGT	GGCACAGCAT	TCTAGGGAGA	AATATGCTTG	TCATCACCGA	AGCCTGATTC	5100
5	CGTAGAGCCA	CACCTTGGTA	AGGGCCAATC	TGCTCACACA	ggatagagag	GGCAGGAGCC	5160
	AGGGCAGAGC	ATATAAGGTG	AGGTAGGATC	AGTTGCTCCT	CACATTTGCT	TCTGACATAG	5220
	TTGTGTTGGG	AGCTTGGATC	GATCCTCTAT	GGTTGAACAA	GATGGATTGC	ACGCAGGTTC	5280
10	TCCGGCCGCT	TGGGTGGAGA	GGCTATTCGG	CTATGACTGG	GCACAACAGA	CARTCGGCTG	5340
	CTCTGATGCC	GCCGTGTTCC	GGCTGTCAGC	GCAGGGGGGC	CCGGTTCTTT	TTGTCAAGAC	5400
	CGACCTGTCC	GGTGCCCTGA	ATGRACTGCA	GGACGAGGCA	GCGCGGCTAT	CGTGGCTGGC	5460
15	CACGACGGGC	GTTCCTTGCG	CAGCTGTGCT	CGACGTTGTC	ACTGAAGCGG	GAAGGGACTG	5520
,,,	GCTGCTATTG	GGCGAAGTGC	CGGGGCAGGA	TCTCCTGTCA	TCTCACCTTG	CTCCTGCCGA	5580
	GAAAGTATCC	ATCATGGCTG	ATGCAATGCG	GCGGCTGCAT	ACGCTTGATC	CGGCTACCTG	5640
	CCCATTCGAC	CACCAAGCGA	AACATCGCAT	CGAGCGAGCA	CGTACTCGGA	TGGAAGCCGG	5700
20	TCTTGTCGAT	CAGGATGATC	TGGACGAAGA	GCATCAGGGG	CTCGCGCCAG	CCGAACTGTT	5760
	CGCCAGGCTC	AAGGCGCGCA	TGCCCGACGG	CGAGGATCTC	GTCGTGACCC	ATGGCGATGC	5820
	CTGCTTGCCG	AATATCATGG	TGGAAAATGG	CCGCTTTTCT	GGATTCATCG	ACTGTGGCCG	5880
25	GCTGGGTGTG	GCGGACCGCT	ATCAGGACAT	AGCGTTGGCT	ACCCGTGATA	TTGCTGAAGA	5940
	GCTTGGCGGC	GAATGGGCTG	ACCGCTTCCT	CGTGCTTTAC	GGTATCGCCG	CTCCCGATTC	6000
	GCAGCGCATC	GCCTTCTATC	GCCTTCTTGA	CGAGTTCTTC	TGAGCGGGAC	TCTGGGGTTC	6060
30	GAAATGACCG	ACCAAGCGAC	GCCCAACCTG	CCATCACGAG	ATTTCGATTC	CACCGCCGCC	6120
	TTCTATGAAA	GCTTGGGCTT	CGGAATCGTT	TTCCGGGACG	CCGGCTGGAT	GATCCTCCAG	6180
	CGCGGGGATC	TCATGCTGGA	GTTCTTCGCC	CACCCCAACT	TGTTTATTGC	AGCTTATAAT	6240
35	GGTTACAAAT	AAAGCAATAG	CATCACAAAT	TTCACAAATA	. AAGCATTTT	TTCACTGCAT	6300
	TCTAGTTGTG	GTTTGTCCAA	ACTCATCAAT	CTATCTTATC	ATGTCTGGAT	cececcece	6360
	ATCCCGTCGA	GAGCTTGGCG	TAATCATGGT	CATAGCTGTT	TCCTGTGTGA	AATTGTTATC	6420
40	CGCTCACAAT	TCCACACAA	ATACGAGCCG	GAAGCATAAA	GTGTAAAGCC	TGGGGTGCCT	6480
	AATGAGTGAG	CTARCTCACA	TTAATTGCGT	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	6540
	ACCTGTCGTG	CCAGCTGCAT	TANTGANTCG	GCCAACGCGC	GGGGAGAGGC	GGTTTGCGTA	6600
45	TTGGGCGCTC	TTCCGCTTCC	TCGCTCACTG	ACTCGCTGCG	CTCGGTCGTT	CGCTGCGGC	6660
	GAGCGGTATO	AGCTCACTCA	AAGGCGGTAA	TACGGTTATC	CACAGAATCA	GGGGATAACG	6720
	CAGGAAAGAI	CATGTGAGCA	AAAGGCCAGC	: AAAAGGCCAG	GAACCGTAAA	AAGGCCGCGT	6780
50	TGCTGGCGTT	TTTCCATAGO	CTCCGCCCCC	CTGACGAGC	TCACAAAAAT	CGACGCTCAA	6840
30	GTCAGAGGTG	GCGAAACCCC	ACAGGACTAT	AAAGATACC	GCCTTTCCC	CCTGGAAGCT	6900
	CCCTCGTGC	CTCTCCTGT	CCGACCCTGC	CGCTTACCG	ATACCTGTCC	GCCTTTCTCC	6960

	CTTCGGGAAG	CGTGGCGCTT	TCTCAATGCT	CACGCTGTAG	GTATCTCAGT	TCGGTGTAGG	7020
5	TCGTTCGCTC	CAAGCTGGGC	TGTGTGCACG	AACCCCCCGT	TCAGCCCGAC	CGCTGCGCCT	7080
	TATCCGGTAA	CTATCGTCTT	GAGTCCAACC	CGGTAAGACA	CGACTTATCG	CCACTGGCAG	7140
	CAGCCACTGG	TAACAGGATT	AGCAGAGCGA	GGTATGTAGG	CGGTGCTACA	GAGTTCTTGA	7200
10	AGTGGTGGCC	TAACTACGGC	TACACTAGAA	GGACAGTATT	TGGTATCTGC	GCTCTGCTGA	7260
	AGCCAGTTAC	CTTCGGAAAA	AGAGTTGGTA	GCTCTTGATC	CGGCAAACAA	ACCACCGCTG	7320
	GTAGCGGTGG	TTTTTTTTTT	TGCAAGCAGC	AGATTACGCG	CAGAAAAAA	GGATCTCAAG	7380
15	AAGATCCTTT	GATCTTTTCT	ACGGGGTCTG	ACGCTCAGTG	GAACGAAAAC	TCACGTTAAG	7440
	GGATTTTGGT	CATGAGATTA	TCAAAAAGGA	TCTTCACCTA	GATCCTTTTA	TAAAAAT	7500
	GAAGTTTTAA	ATCAATCTAA	AGTATATATG	AGTAAACTTG	GTCTGACAGT	TACCAATGCT	7560
20	TAATCAGTGA	GGCACCTATC	TCAGCGATCT	GTCTATTTCG	TTCATCCATA	GTTGCCTGAC	7620
	TCCCCGTCGT	GTAGATAACT	ACGATACGGG	AGGGCTTACC	ATCTGGCCCC	AGTGCTGCAA	7680
	TGATACCGCG	AGACCCACGC	TCACCGGCTC	CAGATTTATC	agcaataaac	CAGCCAGCCG	7740
25	GAAGGGCCGA	GCGCAGAAGT	GGTCCTGCAA	CTTTATCCGC	CTCCATCCAG	TCTATTAATT	7800
20	GTTGCCGGGA	AGCTAGAGTA	AGTAGTTCGC	CAGTTAATAG	TTTGCGCAAC	GTTGTTGCCA	7860
	TTGCTACAGG	CATCGTGGTG	TCACGCTCGT	CGTTTGGTAT	GGCTTCATTC	AGCTCCGGTT	7920
30	CCCAACGATC	AAGGCGAGTT	ACATGATCCC	CCATGTTGTG	CAAAAAAGCG	GTTAGCTCCT	7980
30	TOGGTCCTCC	GATCGTTGTC	AGAAGTAAGT	TGGCCGCAGT	GTTATCACTC	ATGGTTATGG	8040
	CAGCACTGCA	TARTTCTCTT	ACTGTCATGC	CATCCGTAAG	ATGCTTTTCT	GTGACTGGTG	8100
35	AGTACTCAAC	CAAGTCATTC	TGAGAATAGT	GTATGCGGCG	ACCGAGTTGC	TCTTGCCCGG	8160
33	CGTCAATACG	GGATAATACC	GCGCCACATA	GCAGAACTTT	AAAAGTGCTC	ATCATTGGAA	8220
	AACGTTCTTC	GGGGCGAAAA	CTCTCAAGGA	. TCTTACCGCT	GTTGAGATCC	ACTTCGATGT	8280
40	AACCCACTCG	TGCACCCAAC	TGATCTTCAG	CATCTTTAC	TTTCACCAGC	GTTTCTGGGT	8340
40	GAGCAAAAAC	AGGAAGGCAA	AATGCCGCAA	AAAAGGGAAT	AAGGGCGACA	CGGAAATGTT	8400
	GAATACTCAT	ACTCTTCCTT	TTTCAATATI	ATTGAAGCAT	TTATCAGGGT	TATTGTCTCA	8460
	TGAGCGGATA	CATATTTGAA	TGTATTTAGA	AAAATAAACA	AATAGGGGTT	CCGCGCACAT	8520
45	TTCCCCGARA	AGTGCCACCT	ı				8540

(3) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9209 bases

55

TYPE: nucleic acid (B)

STRANDEDNESS: single TOPOLOGY: circular (C) (D)

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: yes (iji)

(iv) ANTI-SENSE: no

(ii)

SEQUENCE DESCRIPTION: SEQ ID NO: 2: (ix)

GACGTCGCGG CCGCTCTAGG CCTCCAAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG	60
AGGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAAAAAAAT TAGTCAGCCA TGCATGGGGC	120
GGAGAATGGG CGGAACTGGG CGGAGTTAGG GGCGGGATGG GCGGAGTTAG GGGCGGGACT	180
ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC TGCCTGCTGG GGAGCCTGGG	240
GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT	300
GGGGAGCCTG GGGACTTTCC ACACCCTAAC TGACACACAT TCCACAGAAT TAATTCCCCT	360
AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC	420
GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG	480
ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA	540
TGGGTGGACT ATTTACGGTA AACTGCCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA	600
AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATTA TGCCCAGTAC	660
ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC	720
ATGGTGATGC GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA	780
TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG	840
GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA	900
CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC	960
CATCACAGAT CTCTCACTAT GGATTTTCAG GTGCAGATTA TCAGCTTCCT GCTAATCAGT	1020
GCTTCAGTCA TAATGTCCAG AGGACAAATT GTTCTCTCCC AGTCTCCAGC AATCCTGTCT	1080
GCATCTCCAG GGGAGAAGGT CACAATGACT TGCAGGGCCA GCTCAAGTGT AAGTTACATC	1140
CACTGGTTCC AGCAGAAGCC AGGATCCTCC CCCAAACCCT GGATTTATGC CACATCCAAC	1200
CTGGCTTCTG GAGTCCCTGT TCGCTTCAGT GGCAGTGGGT CTGGGACTTC TTACTCTCTC	1260
ACAATCAGCA GAGTGGAGGC TGAAGATGCT GCCACTTATT ACTGCCAGCA GTGGACTAGT	1320
AACCCACCCA CGTTCGGAGG GGGGACCAAG CTGGAAATCA AACGTACGGT GGCTGCACCA	1380
TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAACTGC CTCTGTTGTG	1440

55

5

10

15

20

25

30

35

40

45

5	TGCCTGCTGA	ATAACTTCTA	TCCCAGAGAG	GCCAAAGTAC	AGTGGAAGGT	GGATAACGCC	1500
	CTCCAATCGG	GTAACTCCCA	GGAGAGTGTC	ACAGAGCAGG	ACAGCAAGGA	CAGCACCTAC	1560
	AGCCTCAGCA	GCACCCTGAC	GCTGAGCAAA	GCAGACTACG	AGAAACACAA	AGTCTACGCC	1620
10	TGCGAAGTCA	CCCATCAGGG	CCTGAGCTCG	CCCGTCACAA	AGAGCTTCAA	CAGGGGAGAG	1680
	TGTTGAATTC	AGATCCGTTA	ACGGTTACCA	ACTACCTAGA	CTGGATTCGT	GACAACATGC	1740
	GGCCGTGATA	TCTACGTATG	ATCAGCCTCG	ACTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	1800
	GTTTGCCCCT	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	TGTCCTTTCC	1860
15	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	TCTGGGGGGT	1920
15	GGGGTGGGGC	AGGACAGCAA	GGGGGAGGAT	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	1980
	GCGGTGGGCT	CTATGGAACC	AGCTGGGGCT	CGACAGCTAT	GCCAAGTACG	CCCCCTATTG	2040
	ACGTCAATGA	CGGTAAATGG	CCCGCCTGGC	ATTATGCCCA	GTACATGACC	TTATGGGACT	2100
20	TTCCTACTTG	GCAGTACATC	TACGTATTAG	TCATCGCTAT	TACCATGGTG	ATGCGGTTTT	2160
	GGCAGTACAT	CAATGGGCGT	GGATAGCGGT	TTGACTCACG	GGGATTTCCA	AGTCTCCACC	2220
	CCATTGACGT	CAATGGGAGT	TTGTTTTGGC	ACCAAAATCA	ACGGGACTTT	CCAAAATGTC	2280
25	GTAACAACTC	CGCCCCATTG	ACGCAAATGG	GCGGTAGGCG	TGTACGGTGG	GAGGTCTATA	2340
	TAAGCAGAGC	TGGGTACGTC	CTCACATTCA	GTGATCAGCA	CTGAACACAG	ACCCGTCGAC	2400
	ATGGGTTGGA	GCCTCATCTT	GCTCTTCCTT	GTCGCTGTTG	CTACGCGTGT	CCTGTCCCAG	2460
30	GTACAACTGC	AGCAGCCTGG	GGCTGAGCTG	GTGAAGCCTG	GGGCCTCAGT	GAAGATGTCC	2520
	TGCAAGGCTT	CTGGCTACAC	ATTTACCAGT	TACAATATGC	ACTGGGTAAA	ACAGACACCT	2580
	GGTCGGGGCC	TGGAATGGAT	TGGAGCTATT	TATCCCGGAA	ATGGTGATAC	TTCCTACAAT	2640
35	CAGAAGTTCA	AAGGCAAGGC	CACATTGACT	GCAGACAAAT	CCTCCAGCAC	AGCCTACATG	2700
	CAGCTCAGCA	GCCTGACATC	TGAGGACTCT	GCGGTCTATT	ACTGTGCAAG	ATCGACTTAC	2760
	TACGGCGGTG	ACTGGTACTT	CAATGTCTGG	GGCGCAGGGA	CCACGGTCAC	CGTCTCTGCA	2820
40	GCTAGCACCA	AGGGCCCATC	GGTCTTCCCC	CTGGCACCCT	CCTCCAAGAG	CACCTCTGGG	2880
	GGCACAGCGG	CCCTGGGCTG	CCTGGTCAAG	GACTACTTCC	CCGAACCGGT	GACGGTGTCG	2940
	TGGAACTCAG	GCGCCCTGAC	CAGCGGCGTG	CACACCTTCC	CGGCTGTCCT	ACAGTCCTCA	3000
45	GGACTCTACT	CCCTCAGCAG	CGTGGTGACC	GTGCCCTCCA	GCAGCTTGGG	CACCCAGACC	3060
	TACATCTGCA	ACGTGAATCA	CAAGCCCAGC	AACACCAAGG	TGGACAAGAA	AGCAGAGCCC	3120
	AAATCTTGTG						3180
50	CCGTCAGTCT	TCCTCTTCCC	CCCAAAACCC	AAGGACACCC	TCATGATCTC	CCGGACCCCT	3240
						GTTCAACTGG	3300
						GCAGTACAAC	3360
					-30000ioon		3300

5	agcacgtacc	GTGTGGTCAG	CGTCCTCACC	GTCCTGCACC	AGGACTGGCT	GAATGGCAAG	3420
	Gagtacaact	GCAAGGTCTC	CAACAAAGCC	CTCCCAGCCC	CCATCGAGAA	AACCATCTCC	3480
	AAAGCCAAAG	GGCAGCCCCG	AGAACCACAG	GTGTACACCC	TGCCCCCATC	CCGGGATGAG	3540
	CTGACCAAGA	ACCAGGTCAG	CCTGACCTGC	CTGGTCAAAG	GCTTCTATCC	CAGCGACATC	3600
10	GCCGTGGAGT	GGGAGAGCAA	TGGGCAGCCG	GAGAACAACT	ACAAGACCAC	GCCTCCCGTG	3660
	CTGGACTCCG	ACGGCTCCTT	CTTCCTCTAC	agcaagetea	CCGTGGACAA	GAGCAGGTGG	3720
	CAGCAGGGGA	ACGTCTTCTC	ATGCTCCGTG	atgcatgagg	CTCTGCACAA	CCACTACACG	3780
15	CAGAAGAGCC	TCTCCCTGTC	TCCGGGTAAA	TGAGGATCCG	TTAACGGTTA	CCAACTACCT	3840
	AGACTGGATT	CGTGACAACA	TGCGCCCGTG	ATATCTACGT	ATGATCAGCC	TCGACTGTGC	3900
	CTTCTAGTTG	CCAGCCATCT	GTTGTTTGCC	CCTCCCCCGT	GCCTTCCTTG	ACCCTGGAAG	3960
20	GTGCCACTCC	CACTGTCCTT	TCCTAATAAA	atgaggaaat	TGCATCGCAT	TGTCTGAGTA	4020
20	GGTGTCATTC	TATTCTGGGG	cotoccotcc	GGCAGGACAG	CAAGGGGGAG	GATTGGGAAG	4080
	acaatagcag	GCATGCTGGG	GATGCGGTGG	GCTCTATGGA	ACCAGCTGGG	GCTCGACAGC	4140
05	GCTGGATCTC	CCGATCCCCA	GCTTTGCTTC	TCAATTTCTT	ATTTGCATAA	TGAGAAAAA	4200
25	aggaaaatta	ATTTTAACAC	CAATTCAGTA	GTTGATTGAG	CAAATGCGTT	GCCAAAAAGG	4260
	ATGCTTTAGA	GACAGTGTTC	TCTGCACAGA	TAAGGACAAA	CATTATTCAG	AGGGAGTACC	4320
	CAGAGCTGAG	ACTCCTAAGC	CAGTGAGTGG	CACAGCATTC	TAGGGAGAAA	TATGCTTGTC	4380
30	ATCACCGAAG	CCTGATTCCG	TAGAGCCACA	CCTTGGTAAG	GGCCAATCTG	CTCACACAGG	4440
	ATAGAGAGGG	CAGGAGCCAG	GGCAGAGCAT	ataaggtgag	GTAGGATCAG	TTGCTCCTCA	4500
	CATTTGCTTC	TGACATAGTT	GTGTTGGGAG	CTTGGATAGC	TTGGACAGCT	CAGGGCTGCG	4560
35	ATTTCGCGCC	aaacttgacg	GCAATCCTAG	CGTGAAGGCT	GGTAGGATTT	TATCCCCGCT	4620
	GCCATCATGG	TTCGACCATT	GAACTGCATC	GTCGCCGTGT	CCCAAAATAT	GGGGATTGGC	4680
40	AAGAACGGAG	ACCTACCCTG	GCCTCCGCTC	AGGAACGAGT	TCAAGTACTT	CCAAAGAATG	4740
	ACCACAACCT	CTTCAGTGGA	aggtaaacag	AATCTGGTGA	TTATGGGTAG	Garaacctgg	4800
	TTCTCCATTC	CTGAGAAGAA	TCGACCTTTA	aaggacagaa	TTAATATAGT	TCTCAGTAGA	4860
4 5	GAACTCAAAG	AACCACCACG	AGGAGCTCAT	TTTCTTGCCA	aaagtttgga	TGATGCCTTA	4920
	AGACTTATTG	AACAACCGGA	ATTGGCAAGT	aaagtagaca	TGGTTTGGAT	AGTCGGAGGC	49 B0
	AGTTCTGTTT	ACCAGGAAGC	Catgaatcaa	CCAGGCCACC	TTAGACTCTT	TGTGACAAGG	5040
50	ATCATGCAGG	aatttgaaag	TGACACGTTT	TTCCCAGAAA	TTCATTTGGG	Caratatara	5100
	CTTCTCCCAG	AATACCCAGG	CGTCCTCTCT	GAGGTCCAGG	aggaaaaagg	Catcaagtat	5160
	AAGTTTG AA G	TCTACGAGAA	gaaagactaa	CAGGAAGATG	CTTTCAAGTT	CTCTGCTCCC	5220

5	CTCCTAAAGC	TATGCATTTT	TATAAGACCA	TGGGACTTTT	GCTGGCTTTA	GATCAGCCTC	5280
	GACTGTGCCT	TCTAGTTGCC	AGCCATCTGT	TGTTTGCCCC	TCCCCCGTGC	CTTCCTTGAC	5340
	CCTGGAAGGT	GCCACTCCCA	CTGTCCTTTC	СТААТААААТ	GAGGAAATTG	CATCGCATTG	5400
	TCTGAGTAGG	TGTCATTCTA	TTCTGGGGGG	TGGGGTGGGG	CAGGACAGCA	AGGGGAGGA	5460
10	TTGGGAAGAC	AATAGCAUGC	ATGCTGGGGA	TGCGGTGGGC	TCTATGGAAC	CAGCTGGGGC	5520
10	TCGAGCTACT	AGCTTTGCTT	CTCAATTTCT	TATTTGCATA	ATGAGAAAAA	AAGGAAAATT	5580
	AATTTTAACA	CCAATTCAGT	AGTTGATTGA	GCAAATGCGT	TGCCAAAAAG	GATGCTTTAG	5640
15	AGACAGTGTT	CTCTGCACAG	ATAAGGACAA	ACATTATTCA	GAGGGAGTAC	CCAGAGCTGA	5700
15	GACTCCTAAG	CCAGTGAGTG	GCACAGCATT	CTAGGGAGAA	ATATGCTTGT	CATCACCGAA	5760
	GCCTGATTCC	GTAGAGCCAC	ACCTTGGTAA	GGGCCAATCT	GCTCACACAG	GATAGAGAGG	5820
	GCAGGAGCCA	GGGCAGAGCA	TATAAGGTGA	GGTAGGATCA	GTTGCTCCTC	ACATTTGCTT	5880
20	CTGACATAGT	TGTGTTGGGA	GCTTGGATCG	ATCCTCTATG	GTTGAACAAG	ATGGATTGCA	5940
	CGCAGGTTCT	CCGGCCGCTT	GGGTGGAGAG	GCTATTCGGC	TATGACTGGG	CACAACAGAC	6000
	AATCGGCTGC	TCTGATGCCG	CCGTGTTCCG	GCTGTCAGCG	CAGGGGCGCC	CGGTTCTTTT	6060
25	TGTCAAGACC	GACCTGTCCG	GTGCCCTGAA	TGAACTGCAG	GACGAGGCAG	CGCGGCTATC	6120
	GTGGCTGGCC	ACGACGGGCG	TTCCTTGCGC	AGCTGTGCTC	GACGTTGTCA	CTGAAGCGGG	6180
	AAGGGACTGG	CTGCTATTGG	GCGAAGTGCC	GGGCAGGAT	CTCCTGTCAT	CTCACCTTGC	6240
30	TCCTGCCGAG	AAAGTATCCA	TCATGGCTGA	TGCAATGCGG	CGGCTGCATA	CGCTTGATCC	6300
	GGCTACCTGC	CCATTCGACC	ACCAAGCGAA	ACATCGCATC	GAGCGAGCAC	GTACTCGGAT	6360
	GGAAGCCGGT	CTTGTCGATC	AGGATGATCT	GGACGAAGAG	CATCAGGGGC	TCGCGCCAGC	6420
35	CGAACTGTTC	GCCAGGCTCA	AGGCGCGCAT	GCCCGACGGC	GAGGATCTCG	TCGTGACCCA	6480
	TGGCGATGCC	TGCTTGCCGA	ATATCATGGT	GGAAAATGGC	CGCTTTTCTG	GATTCATCGA	6540
	CTGTGGCCGG	CTGGGTGTGG	CGGACCGCTA	TCAGGACATA	GCGTTGGCTA	CCCGTGATAT	6600
40	TGCTGAAGAG	CTTGGCGGCG	AATGGGCTGA	CCGCTTCCTC	GTGCTTTACG	GTATCGCCGC	6660
	TCCCGATTCG	CAGCGCATCG	CCTTCTATCG	CCTTCTTGAC	GAGTTCTTCT	GAGCGGGACT	6720
	CTGGGGTTCG	AAATGACCGA	CCAAGCGACG	CCCAACCTGC	CATCACGAGA	TTTCGATTCC	6780
45	ACCGCCGCCT	TCTATGAAAG	GTTGGGCTTC	GGAATCGTTT	TCCGGGACGC	CGGCTGGATG	6840
	ATCCTCCAGC	GCGGGGATCT	CATGCTGGAG	TTCTTCGCCC	ACCCCAACTT	GTTTAT TGCA	6900
	GCTTATAATG	GTTACAAATA	AAGCAATAGC	ATCACAAATT	тсасааатаа	AGCATTTTTT	6960
50	TCACTGCATT	CTAGTTGTGG	TTTGTCCAAA	CTCATCAATC	TATCTTATCA	TGTCTGGATC	7020
	GCGGCCGCGA	TCCCGTCGAG	AGCTTGGCGT	AATCATGGTC	ATAGCTGTTT	CCTGTGTGAA	7080
	ATTGTTATCC	GCTCACAATT	CCACACAACA	TACGAGCCGG	AAGCATAAAG	TGTAAAGCCT	7140

5	GGGGTGCCTA	ATGAGTGAGC	TAACTCACAT	TAATTGCGTT	GCGCTCACTG	CCCGCTTTCC	7200
	agtc gggaa a	CCTGTCGTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	7260
	GTTTGCGTAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TCGGTCGTTC	7320
	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	aggeggtaat	ACGGTTATCC	acagaatcag	7380
10	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	aaggccagca	AAAGGCCAGG	AACCGTAAAA	7440
	AGGCCGCGTT	GCTGGCGTTT	TTCCATAGGC	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	7500
	GACGCTCAAG	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	AAGATACCAG	CCCTTTCCCC	7560
15	CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTC	CGACCCTGCC	GCTTACCGGA	TACCTGTCCG	7620
	CCTTTCTCCC	TTCGGGAAGC	GTGGCCCTTT	CTCAATGCTC	ACCCTGTAGG	TATCTCAGTT	7680
	CGGTGTAGGT	CGTTCGCTCC	argetggget	GTGTGCACGA	ACCCCCCGTT	CAGCCCGACC	7740
20	GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	7800
	CACTGGCAGC	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	7860
	AGTTCTTGAA	GTGGTGGCCT	AACTACGGCT	acactagaag	GACAGTATTT	GGTATCTGCG	7920
25	CTCTGCTGAA	GCCAGTTACC	TTCGGAAAAA	GAGTTGGTAG	CTCTTGATCC	GGCAAACAAA	7980
	CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	GATTACGCGC	AGAAAAAAG	8040
	GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	CGGGGTCTGA	CCCTCAGTGG	AACGAAAACT	8100
30	CACGTTAAGG	GATTTTGGTC	atgagattat	CAAAAAGGAT	CTTCACCTAG	ATCCTTTTAA	8160
	attaaaaatg	AAGTTTTAAA	TCAATCTAAA	GTATATATGA	GTAAACTTGG	TCTGACAGTT	8220
	ACCAATGCTT	aatcagtgag	GCACCTATCT	CAGCGATCTG	TCTATTTCGT	TCATCCATAG	8280
35	TTGCCTGACT	CCCCGTCGTG	TAGATAACTA	CGATACGGGA	GGGCTTACCA	TCTGGCCCCA	8340
33	GTGCTGCAAT	GATACCGCGA	GACCCACGCT	CACCGGCTCC	AGATTTATCA	GCAATAAACC	8400
	AGCCAGCCGG	AAGGGCCGAG	CGCAGAAGTG	GTCCTGCAAC	TTTATCCGCC	TCCATCCAGT	8460
40	CTATTAATTG	TTGCCGGGAA	GCTAGAGTAA	GTAGTTCGCC	AGTTAATAGT	TTGCGCAACG	8520
	TTGTTGCCAT	TGCTACAGGC	ATCGTGGTGT	CACGCTCGTC	GTTTGGTATG	GCTTCATTCA	8580
	GCTCCGGTTC	CCAACGATCA	AGGCGAGTTA	CATGATCCCC	CATGTTGTGC	AAAAAAGCGG	8640
45	TTAGCTCCTT	CGGTCCTCCG	ATCGTTGTCA	GAAGTAAGTT	GGCCGCAGTG	TTATCACTCA	8700
	TGGTTATGGC	AGCACTGCAT	AATTCTCTTA	CTGTCATGCC	ATCCGTAAGA	TGCTTTTCTG	8760
	TGACTGGTGA	GTACTCAACC	AAGTCATTCT	GAGAATAGTG	TATGCGGCGA	CCGAGTTGCT	8820
50	CTTGCCCGGC	GTCAATACGG	GATAATACCG	CGCCACATAG	CAGAACTTTA	AAAGTGCTCA	8886
	TCATTGGAAA	ACGTTCTTCG	GGGCGAAAAC	TCTCAAGGAT	CTTACCGCTG	TTGAGATCCA	8940
	GTTCGATGTA	ACCCACTCGT	GCACCCAACT	GATCTTCAGO	ATCTTTTACT	TTCACCAGCG	9000

	TT	TCTGGGT	G AGCAA	AAACA GGAAGGCAAA	ATGCCGCAAA	AAAGGGAATA	AGGGCGACAC	9060
5	GG	AAATGTT	G AATAC	CATA CTCTTCCTTT	TTCAATATTA	TTGAAGÇATT	TATCAGGGTT	9120
	TA	TGTCTCA	r GAGCG	GATAC ATATTTGAAT	GTATTTAGAA	AAATAAACAA	ATAGGGGTTC	9180
	CG	CGCACAT	TCCCC	GAAAA GTGCCACCT				9209
10	(4)	INFO	RMATI	ON FOR SEQ ID	NO: 3:			
		(i)	SEQUI	ENCE CHARACT	ERISTICS:			
15			(B) (C)	LENGTH: 54 bas TYPE: nucleic aci STRANDEDNESS TOPOLOGY: line	d S: single			
20		(ii)	MOLE	CULE TYPE: DN	IA (genomic)		
		(iii)	HYPO	THETICAL: yes				
		(iv)	ANTI-S	SENSE: no				
25		(ix)	SEQUI	ENCE DESCRIPT	TION: SEQ	ID NO: 3:		
			C ACA GA	AT CTC TCA CCA TO	GG ATT TTC A	AGG TBC AGA	TTA TCA GCT	52 2
30	(5)	INFO	RMATI	ON FOR SEQ ID	NO: 4:			
		(i)	SEQUI	ENCE CHARACT	ERISTICS:			
35			(B) '(C)	LENGTH: 30 bas TYPE: nucleic aci STRANDEDNESS TOPOLOGY: line	d S: single			
40		(ii)	MOLE	CULE TYPE: DN	IA (genomic)		
		(iii)	HYPO'	THETICAL: yes				
		(iv)	ANTI-S	SENSE: yes				
45		(ix)	SEQUI	ENCE DESCRIPT	TION: SEQ	ID NO: 4:		
50		5' TG	C AGC A	TC CGT ACG TTT GA	AT TTC CAG	CTT 3'		30
	(6)	INFO	RMATI	ON FOR SEQ ID	NO: 5:			
			101011 2 1 1	ON FOR BEAGIN	110. 0.			
		(i)		ENCE CHARACT				

5			(F (E (C (I	3) C)	TYI STI	PE: RAN	nucle DED	eic a NES Elir	cid SS: s		e							
		(ii)	M	OLI	ECU.	LE T	rypi	E: D	NA (gene	omic)						
10		(Hi)	H	YPC	THI	etic	CAL:	yes										
		(iv)	A	NTI	-SEN	ISE:	no											
15		(ix)	S	EQU	ENG	CE I	ESC	CRIF	TIO	N: S	SEQ	ID N	10:	5:				
	ATG	GAT	TTT	CAG	GTG	CAG	ATT	ATC	AGC	TTC	CTG	СТА	ATC	AGT	GCT	TCA	GTC	51
20	ATA	ATG	TCC	AGA	GGG	CAA	ATT	GTT	CTC	TCC	CAG	TCT	CCA	GCA	ATC	CTG	TCT	102
	GCA	TCT	CCA	GGG	GAG	AAG	GTC	ACA	ATG	ACT	TGC	AGG	GCC	AGC	TCA	AGT	GTA	153
	AGT	TAC	ATC	CAC	TGG	TTC	CAG	CAG	AAG	CCA	GGA	TCC	TCC	CCC	AAA	CCC	TGG	204
25	ATT	TAT	GCC _*	ACA	TCC	AAC	CTG	GCT	TCT	GGA	GTC	CCT	GTT	CGC	TTC	AGT	GGC	255
	AGT	GGG	TCT	GGG	ACT	TCT	TAC	TCT	CTC	ACA	ATC	AGC	AGA	GTG	GAG	GCT	GAA	306
	GAT	GCT	GCC	ACT	TAT	TAC	TGC	CAG	CAG	TGG	ACT	AGT	AAC	CCA	CCC	ACG	TTC	357
30	GGA	GGG	GGG	ACC	AAG	CTG	GAA	ATC	AAA									384
	(7)	INF	ORN	/IAT	ION	FOI	RSE	Q II	NO	: 6:								
35		(i)	SI	EQU	ENC	CE C	HAI	RAC'	rer:	ISTI	CS:							
40			(A (B (C (D	;) ;)	TYF	E: 1	nucle DED	7 ba eic ac NES : lin	cid SS: s	ingl	e							
		(ii)	M	OLE	CUI	LE I	YPE	: D	NA (geno	mic))						
45		(iii)	н	YPO	THE	ETIC	AL:	ves										
45		(iv)			SEN			•							-			
								·nin	mr o i	~	ъ.			_				
50		(ix)	51	ي W ∩	rin(E D	正の(RIP	1101	N: S	正ん .	ID N	O: (o:				
		5' G	SCG G	CT C	CC A	cg c	CGT C	STC C	TG T	rcc c	CAG 3	, .						27

	(8)	IN	FO!	FORMATION FOR SEQ ID NO: 7:														
5		(i)		SEQ	UEN	ICE	CHA	ARA	CTE	RIS.	rics	: :						
10				(A) (B) (C) (D)	TY ST	PE:	TH: nuc NDE LOG	cleic DNE	acid ESS:	sins	gle							
		(ii))	моі	LECI	JLE	TYF	E:]	DNA	(gei	nomi	.c)						
		(iii	i)	HYF	OTF	ET	CAI	_: y∈	s									
15		(iv	·)	ANT	'I-SE	NSE	Σ: y ε	es										
		(ix	:)	SEQ	UEN	ICE	DES	CRI	PTI	ON:	SEG	Q ID	NO:	7 :				
20		5'	GGS	TGT	TGT	GCT	AGC	TGM	RGA	GAC	RGT	GA .	3 '	29				
										_								
	(9)	IN	FOI	RMA	TIOI	N FC	OR S	EQ I	D N	O: 8	3:							
25		(i)	•	SEQ	UEN	ICE	CHA	ARA	CTE:	RIST	rics	:						
30				(A) (B) (C) (D)	TY SI	PE:	TH: nuc NDE: LOG	leic DNE	acid 2SS:	sing	gle							
30		(ii))	MOI	ECU	JLE	TYF	E : 1	DNA	(ger	nomi	c)						
		(iii	i)	НҮР	OTE	IETI	CAL	.: ye	s									
35		(iv)	ANT	I-SE	NSE	E: no)										
		(ix)	SEQ	UEN	ICE	DES	CRI	PTI	ON:	SEG	(ID	NO:	8:				
40	ATG	GGT	TGG	AGC	CTC	ATC	TTG	СТС	TTC	CTT	GTC	GCT	GTT	GCT	ACG	CGT	GTC	51
	CTG	TCC	CAG	GTA	CAA	CTG	CAG	CAG	CCT	GGG	GCT	GAG	CTG	GTG	AAG	ССТ	GGG	102
	GCC	TCA	GTG	AAG	ATG	TCC	TGC	AAG	GCT	TCT	GGC	TAC	ACA	TTT	ACC	AGT	TAC	153
45	AAT	ATG	CAC	TGG	GTA	AAA	CAG	ACA	CCT	GGT	CGG	GGC	CTG	GAA	TGG	ATT	GGA	204
	GCT	ATT	TAT	CCC	GGA	AAT	GGT	GAT	ACT	TCC	TAC	AAT	CAG	AAG	TTC	AAA	GGC	255
				TTG														306
50				ACA														357
				GGT GCA	GAC	TGG	TAC	TTC	TAA	GTC	TGG	GGC	GCA	GGG	ACC	ACG	GTC	408 420

TABLE OF CONTENTS

5	A.	FIEI	LD OF	THE I	NVEN	TION
	B.	BAC	KGRO	UND (OF TH	E INVENTION
	C,	SUM	IMARY	OFT	HE IN	VENTION
10	D.	BRII	EF DE	SCRIP	TION	OF THE DRAWINGS
	E.	DET	AILEI	DESC	CRIPT	ION OF PREFERRED EMBODIMENTS
	F.	EXA	MPLE	S		
15		I.	RAD	IOLAE	BELEI	ANTI-CD20 ANTIBODY 2B8
			A.	Anti-	-CD20	Monoclonal Antibody (Murine) Production ("2B8")
20			B.	Prep	aratio	n of 2B8-MX-DTPA Conjugate
20				i.	MX-	DTPA
				ii.	Prep	paration of 2B8
25				iii.	Conj	ugation of 2B8 with MX-DTPA
				iv.	Dete	rmination of MX-DTPA Incorporation
				v.	Imm	unoreactivity of 2B8-MX-DTPA
30				vi.	Prep	earation of Indium-[111]-labeled 2B8-MX-DTPA ("I2B8")
				vii.	Prep	paration of Yttrium-[90]-labeled 2B8-MX-DTPA ("Y2B8")
			C.	Non-	Huma	n Animal Studies
35				i.	Dist	ribution of Radiolabeled 2B8-MX-DTPA
				ii.	Tum	or Localization of I2B8
40				iii.		istribution and Tumor Localization Studies with olabeled 2B8-MX-DTPA
			D.	Hum	an Stu	ndies
45				i.		and 2B8-MX-DTPA: Immunohistology Studies Human Tissues
				ii.		ical Analysis of I2B8 (Imaging) and Y2B8 rapy)
50					a.	Phase I/II Clinical Trial: Single Dose Therapy Study
					b.	Phase I/II Clinical Trial: Multiple Dose Therapy Study
55						

Claims

- An immunologically active, chimeric anti-CD20 antibody obtainable from a transfectoma which secretes said anti-CD20 antibody; said transfectoma being identified by ATCC deposit number 69119.
- A monoclonal antibody obtainable from a hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collection deposit number HB 11388.
- An antibody according to claim 1 or claim 2, for use as a medicament.
- An antibody according to any one of the preceding claims which is radiolabelled.
- An antibody according to claim 4, which is radiolabelled with a radiolabel selected from yttrium (90), indium (111), and iodine (131).
- 6. An antibody according to claim 5, wherein the radiolabel is yttrium (90).
- Use of an antibody according to any one of the preceding claims for the manufacture of a medicament for the treatment of B cell lymphoma in a human.
- Use according to claim 7, wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human ("mg/kg").
- Use according to claim 7 or claim 8, wherein a second therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody is administered to said human. 25
 - 10. Use according to claim 9, wherein said second therapeutically effective amount of said antibody is administered to said human within about seven days of first administration of said antibody to said human.
- 11. Use according to claim 9 or claim 10, wherein a third therapeutically effective amount of at least one immunologically active chimeric anti-CD20 antibody is administered to said human.
 - 12. Use according to claim 11, wherein said third therapeutically effective amount of said antibody is administered to said human within about fourteen days of first administration of said antibody to said human.
 - 13. Use according to claim 7 or claim 8, wherein a radiolabelled anti-CD20 antibody is administered to said human at a second administration period.
- 14. A hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collec-40 tion deposit number HB 11388.

Patentansprüche

- Immunologisch aktiver, chimärer Anti-CD20-Antikörper, erhältlich von einem Transfektom, welches den Anti-CD20-Antikörper sekretiert, wobei das Transfectom durch ATCC Hinterlegungsnummer 69119 identifiziert wird.
 - Monoklonaler Antikörper, erhältlich aus einem Hybridom, welches den Anti-CD20-Antikörper sekretiert, wobei das Hybridom durch American Type Culture Collection Hinterlegungsnummer HB 11388 identifiziert wird.
- Antikörper nach Anspruch 1 oder 2 zur Verwendung als Arzneimittel.
 - Antikörper nach einem der vorstehenden Ansprüche, der radiomarkiert ist.
- Antikörper nach Anspruch 4, der radiomarkiert ist mit einer Radiomarkierung ausgewählt aus Yttrium(90), Indium(111) und Jod(131).
 - Antikörper nach Anspruch 5, worin die Radiomarkierung Yttrium(90) ist.

10

5

15

20

35

45

- 7. Verwendung eines Antikörpers nach einem der vorstehenden Ansprüche zur Herstellung eines Arzneimittels zur Behandlung von B-Zellen-Lymphom in einem Menschen.
- 8. Verwendung nach Anspruch 7, wobei die Menge des dem Menschen verabreichten Antikörpers zwischen etwa 0,001 und etwa 30 Milligramm des Antikörpers pro Kilogramm Körpergewicht des Menschen ("mg/kg") liegt.
- Verwendung nach Anspruch 7 oder Anspruch 8, wobei eine zweite therapeutisch wirksame Menge wenigstens eines immunologisch aktiven, chimären Anti-CD20-Antikörpers an den Menschen verabreicht wird.
- 10. Verwendung nach Anspruch 9, wobei die zweite therapeutisch wirksame Menge des genannten Antikörpers an den betreffenden Menschen innerhalb von etwa sieben Tagen ab der ersten Gabe des Antikörpers an diesen Menschen verabreicht wird.
 - 11. Verwendung nach Anspruch 9 oder Anspruch 10, wobei eine dritte therapeutisch wirksame Menge wenigstens eines immunologisch aktiven, chimären Anti-CD20-Antikörpers an den betreffenden Menschen verabreicht wird.
 - 12. Verwendung nach Anspruch 11, wobei die dritte therapeutisch wirksame Menge des genannten Antikörpers an den betreffenden Menschen innerhalb von etwa vierzehn Tagen ab der ersten Gabe des Antikörpers an diesen Menschen verabreicht wird.
 - 13. Verwendung nach Anspruch 7 oder 8, wobei dem betreffenden Menschen zu einem zweiten Verabreichungs-Zeitraum ein radiomarkierter Anti-CD20-Antikörper verabreicht wird.
 - **14.** Hybridom, welches Anti-CD20-Antikörper sekretiert, wobei dieses Hybridom durch American Type Culture Collection Hinterlegungsnummer HB 11388 identifiziert wird.

Revendications

5

15


20

25

30

- Anticorps anti-CD20 chimère, immunologiquement actif, pouvant être obtenu à partir d'un transfectome qui sécrète ledit anticorps anti-CD20; ledit transfectome étant identifié par le numéro de dépôt ATCC 69119.
 - Anticorps monoclonal pouvant être obtenu à partir d'un hybridome qui sécrète l'anticorps anti-CD20, ledit hybridome étant identifié par le numéro de dépôt de l'American Type Culture Collection HB 11388.
- 35 3. Anticorps suivant la revendication 1 ou la revendication 2, destiné à être utilisé comme médicament.
 - 4. Anticorps suivant l'une quelconque des revendications précédentes, qui est radiomarqué.
- 5. Anticorps suivant la revendication 4, qui est radiomarqué avec un radiomarqueur choisi entre l'yttrium (90), l'indium (111) et l'iode (131).
 - 6. Anticorps suivant la revendication 5, dans lequel le radiomarqueur est l'yttrium (90).
- 7. Utilisation d'un anticorps suivant l'une quelconque des revendications précédentes pour la production d'un médicament destiné au traitement d'un lymphome à lymphocytes B chez un patient humain.
 - 8. Utilisation suivant la revendication 7, dans laquelle la quantité de l'anticorps administrée au patient humain va d'environ 0,001 à environ 30 mg d'anticorps par kilogramme de poids corporel dudit patient humain ("mg/kg").
- 50 9. Utilisation suivant la revendication 7 ou la revendication 8, dans laquelle une deuxième quantité thérapeutiquement efficace d'au moins un anticorps anti-CD20 chimère, immunologiquement actif, est administrée au patient humain.
 - 10. Utilisation suivant la revendication 9, dans laquelle la deuxième quantité thérapeutiquement efficace de l'anticorps est administrée au patient humain dans les limites d'environ 7 jours après la première administration dudit anticorps audit patient humain.
 - 11. Utilisation suivant la revendication 9 ou la revendication 10, dans laquelle une troisième quantité thérapeutiquement efficace d'au moins un anticorps anti-CD20 chimère immunologiquement actif est administrée au patient humain.

	12.	Utilisation suivant la revendication 11, dans laquelle la troisième quantité thérapeutiquement efficace de l'anticorps est administrée au patient humain dans les limites d'environ 14 jours après la première administration dudit anticorps audit patient humain.
5	13.	Utilisation suivant la revendication 7 ou la revendication 8, dans laquelle un anticorps anti-CD20 radiomarqué est administré au patient humain à une seconde période d'administration.
10	14.	Hybridome qui sécrète un anticorps anti-CD20, ledit hybridome étant identifié par le numéro de dépôt de l'American Type Culture Collection HB 11388.
15		
20		
25		
30		
35		
40		
45		
50		



60	AATAGCTCAG	RIGIN=332bp CTACTTCTGG	SV40 01	CCTCCAAAAA		LINKER #1 GACGTCGCGG
120	TGCATGGGGC	TAGTCAGCCA	TAAAAAAAAT	TCTGCATAAA	GGCCTCGGCC	AGGCCGAGGC
180	GGGCGGGACT	GCGGAGTTAG	GGCGGGATGG	CGGAGTTAGG	CGGAACTGGG	GGAGAATGGG
240	GGAGCCTGGG	TGCCTGCTGG	TGCATACTTC	ATGCATGCTT	ACTAATTGAG	ATGGTTGCTG
300			AGATGCATGC	TGACTAATTG	ACCTGGTTGC	GACTTTCCAC
360 1	TAATTCCCCT 360		TGACACACAT	ACACCCTAAC	GGGACTTTCC	GGGGAGCCTG
420	GGAGTTCCGC	GCCCATATAT	TTAGTTCATA	TACGGGGTCA	AGTAATCAAT	AGTTATTAAT
480	CCGCCÇATTG		GGCTGACCGC		TTACGGTAAA	GTTACATAAC
540	TTGACGTCAA	ER=567bp GGACTTTCCA	TER-ENHANCE ACGCCAATAG	CMV PROMO TCCCATAGTA	TGACGTATGT	ACGTCAATAA
600	TCATATGCCA	ATCAAGTGTA	TTGGCAGTAC	AACTGCCCAC	ATTTACGGTA	TGGGTGGACT
660	TGCCCAGTAC	CCTGGCATTA	AAATGGCCCG	CAATGACGGT	CTATTGACGT	AGTACGCCCC
720	CGCTATTACC	TATTAGTCAT	TACATCTACG	TACTTGGCAG	GGGACTTTCC	ATGACCTTAT
780	CTCACGGGGA	AGCGGTTTGA	GGGCGTGGAT	GTACATCAAT	GGTTTTGGCA	ATGGTGATGC
840	AAATCAACGG	TTTGGCACCA	GGGAGTTTGT	TGACGTCAAT	TCCACCCCAT	TTTCCAAGTC
900	TAGGCGTGTA	AAATGGGCGG	CCATTGACGC		AATGTCGTAA	GACTTTCCAA
960			#3=76bp TACGTGAACC	CAGAGCTGGG 727 8		
1020		TGGGGCTCCT	GCTCAGCTCC	GAGGGTCCCC	CTCTCACCAT	Bgl CATCAC <u>AGAT</u>
1080	GGCTGCACCA	07 108 AACGTACGGT 62 3 Bsi WI	GTGGAAATCA	1 101 102 TGGTACCAAG	+:	CTCCCAGGTG
1140	CTCTGTTGTG	CTGGAACTGC	CAGTTGAAAT	ATCTGATGAG	TCTTCCCGCC	TCTGTCTTCA
1200			GCCAAAGTAC			
1260	CODON CAGÇACCTAC	CID & STOP ACAGCAAGGA	107 AMINO A ACAGAGCAGG	STANT 324bp GGAGAGTGTC	GTAACTCCCA	HUMAN CTCCAATCGG
1320	AGTCTACGCC	AGAAACACAA	GCAGACTACG	GCTGAGCAAA	GCACCCTGAC	AGCCTCAGCA
1380	CAGGGGAGAG	AGAGCTTCAA	CCCGTCACAA	CCTGAGCTCG	CCCATCAGGG	STOP
			4=85bn	LINKER #	RI	LIGHT CHAIN Eco
1440	GACAACATGC	CTGGATTCGT				
1500	GCCATCTGTT	CTAGTTGCCA	ACTGTGCCTT	ATCAGCCTCG	TCTACGTATG	GGCCGTGATA

FIG. 2A

GTTTGCCCCT	CCCCCGTGCC			CCACTCCCAC	TGTCCTTTCC	1560
TAATAAAATG	AGGAAATTGC	BGH poly ATCGCATTGT	A=231bp CTGAGTAGGT	GTCATTCTAT	TCTGGGGGGT	1620
GGGGTGGGC	AGGACAGCAA	GGGGGAGGAT	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	1680
GCGGTGGGCT	CTATGGAACC	LINKER # AGCTGGGGCT 02 3	5=15bp CGACAGCTAT 1717 8	GCCAAGTACG	CCCCCTATTG	1740
ACGTCAATGA	CGGTAAATGG	CCCGCCTGGC	ATTATGCCCA	GTACATGACC	TTATGGGACT	1800
TTCCTACTTG				TACCATGGTG	ATGCGGTTTT	1860
	CMV	PROMOTER-	ENHANCER=33	4bp		
				GGGATTTCCA	•	1920
CCATTGACGT	CAATGGGAGT	TTGTTTTGGC	ACCAAAATCA	ACGGGACTTT	CCAAAATGTC	1980
			GCGGTAGGCG	TGTACGGTGG		2040
TAAGCAGAGC	MKER #6=7bi	CTCACATTCA	GTGATCAGCA	CTGAACACAG		2100
1	1 2 2058 9		R=51bp		1 2 Nhe I	
START HEAV		GCTCTTCCTT	GTCGCTGTTG	-5 -4 -		2160
AAGGGCCCAT	CGGTCTTCCC	CCTGGCACCC	TCCTCCAAGA	GCACCTCTGG	GGGCACAGCG	2220
GCCCTGGGCT	GCCTGGTCAA	GGACTACTTC	CCCGAACCGG	TGACGGTGTC	GTGGAACTCA	2280
GGCGCCCTGA				TACAGTCCIC	AGGACTC FAC	2340
	H	HUMAN GAMMA	A 1 CONSTANT	Γ		
TCCCTCAGCA		CGTGCCCTCC = 330 AMINO A		GCACCCAGAC	CTACATCTGC	2400
AACGTGAATC	ACAAGCCCAG	CAACACCAAG	GTGGACAAGA	AAGCAGAGCC	CAAATCTTGT	2460
GACAAAACTC	ACACATGCCC	ACCGTGCCCA	GCACCTGAAC	TCCTGGGGGG	ACCGTCAGTC	2520
ттсстсттсс	CCCCAAAACC	CAAGGACACC	CTCATGATCT	CCCGGACCCC	TGAGGTCACA	2580
TGCGTGGTGG	TGGACGTGAG	CCACGAAGAC	CCTGAGGTCA	AGTTCAACTG	GTACGTGGAC	2640
GGCGTGGAGG	TGCATAATGC	CAAGACAAAG	CCGCGGGAGG	AGCAGTACAA	CAGCACGTAC	2700
CGTGTGGTCA	GCGTCCTCAC	CGTCCTGCAC	CAGGACTGGC	TGAATGGCAA	GGACTACAAG	2760
TGCAAGGTCT	CCAACAAAGC	CCTCCCAGCC	CCCATCGAGA	AAACCATCTC	CAAAGCCAAA	2820
GGGCAGCCCC	GAGAACCACA	GGTGTACACC	CTGCCCCCAT	CCCGGGATGA	GCTGACCAGG	2880
AACCAGGTCA	GCCTGACCTG	CCTGGTCAAA	GGCTTCTATC	CCAGCGACAT	CGCCGTGGAG	2940
TGGGAGAGCA	ATGGGCAGCC	GGAGAACAAC	TACAAGACCA	CGCCTCCCGT	GCTGGACTCC	3000

FIG. 2B

BACGGCTCCT	ICHICCICIA	CAGCAAGCIC	ALLGIGGALA	AUAULAUUTU	GLAGLAGGG	3060
AACGTCTTCT	CATGCTCCGT	GATGCATGAG	GCTCTGCACA	ACCACTACAC	GCAGAAGAGC	3120
S	TOP HEAVY CI	HAIN Bam H	T T	INKER #7=81	hn	
	CTCCGGGTAA			ACCAACTACC	TAGACTGGAT	3180
TCGTGACAAC	ATGCGGCCGT	GATATCTACG	TATGATCAGC	CTCGACTGTG 3225 6	CCTTCTAGTT	3240
	TGTTGTTTGC					3300
CCACTGTCCT	INE GROWTH TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3360
CTATTCTGGG	GGGTGGGGTG	GGGCAGGACA	GCAAGGGGGA			3420
				LINKER #8:	=34bp	
GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	AACCAGCTGG 3456 7	GGCTCGACAG	CGCTGGATCT	3480
CCCGATCCCC 3490	AGCTTTGCTT 1	CTCAATTTCT	TATTTGCATA	ATGAGAAAAA	AAGGAAAATT	3540
AATTTTAACA	*CCAATTCAGT					3600
	MC	DUSE BETA G	LOBIN MAJOR	PROMOTER=3	66bp	
	CTCTGCACAG					3660
	CCAGTGAGTG					3720
	GTAGAGCCAC					3780
GCAGGAGCCA	GGGCAGAGCA					3840
CTGACATAGT	TGTGTTGGGA 3856 7	GCTTGGATAG	CTTGGACAGC 3875 6	NTRANSLATED TCAGGGCTGC	GATTTCGCGC START DHFR	3900
CAAACTTGAC	GGCAATCCTA	GCGTGAAGGC	TGGTAGGATT	TTATCCCCGC	TGCCATCATG 3957 8	3960
GTTCGACCAT	TGAACTGCAT	CGTCGCCGTG	TCCCAAAATA	TGGGGATTGG	CAAGAACGGA	4020
GACCTACCCT	GGCCTCCGCT	CAGGAACGAG	TTCAAGTACT	TCCAAAGAAT	GACCACAACC	4080
TCTTCAGTGG	AAGGTAAACA			GGAAAACCTG & STOP CODO		4140
CCTGAGAAGA	ATCGACCTTT	AAAGGACAGA	ATTAATATAG	TTCTCAGTAG	AGAACTCAAA	4200
GAACCACCAC	GAGGAGCTCA	TTTTCTTGCC	AAAAGTTTGG	ATGATGCCTT	AAGACTTATT	4260
GAACAACCGG	AATTGGCAAG	TAAAGTAGAC	ATGGTTTGGA	TAGTCGGAGG	CAGTTCTGTT	4320
TACCAGGAAG	CCATGAATCA	ACCAGGCCAC	CTTAGACTCT	TTGTGACAAG	GATCATGCAG	4380
GAATTTGAAA	GTGACACGTT	TTTCCCAGAA	ATTGATTTGG	GGAAATATAA	ACTTCTCCCA	4440
GAATACCCAG	GCGTCCTCTC	TGAGGTCCAG	GAGGAAAAAG	GCATCAAGTA	TAAGTTTGAA	4500

FIG. 2C

STOP DHFR GTCTACGAGA AGAAAGACTA ACAGGAAGAT GCTTTCAAGT TCTCTGCTCC CCTCCTAAAG 4560 4521 2 LINKER #10=10bp 3' UNTRANSLATED DHFR=82bp T AGATCAGCOT CGACTGTSSS 4620 4603 4 4613 4 TCATGCATTT TTATAAGACC ATGGGACTTT TGCTGGCTTT TICTAGTIGC CAGCCATCIG TIGTITGCCC CICCCCGTG CCTICCTTGA CCCTGGAAGG 4680 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp
TGCCACTCCC ACTGTCCTTT CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG 4740 GTGTCATTCT ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA 4800 CAATAGCAGG CATGCTGGGG ATGCGGTGGG CTCTATGGAA CCAGCTGGGG CTCGAGCTAC 4860 TAGCTTTGCT TCTCAATTTC TTATTTGCAT AATGAGAAAA AAAGGAAAAT TAATTTTAAC **4920** ACCAATTCAG TAGTTGATTG AGCAAATGCG TTGCCAAAAA GGATGCTTTA GAGACAGTGT 4980 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp TCTCTGCACA GATAAGGACA AACATTATTC AGAGGGAGTA CCCAGAGCTG AGACTCCTAA 5040 GCCAGTGAGT GGCACAGCAT TCTAGGGAGA AATATGCTTG TCATCACCGA AGCCTGATTC 5100 CGTAGAGCCA CACCTTGGTA AGGGCCAATC TGCTCACACA GGATAGAGAG GGCAGGAGCC 5160 AGGGCAGAGC ATATAAGGTG AGGTAGGATC AGTTGCTCCT CACATTTGCT TCTGACATAG 5220 LINKER #12=21bp | START NEO
TIGIGITGGG AGCITGGATC GATCCTCTAT GGTTGAACAA GATGGATTGC ACGCAGGTTC 5280
5227 8 5248 9 TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG GCACAACAGA CAATCGGCTG 5340 CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC CCGGTTCTTT TTGTCAAGAC 5400 NEOMYCIN PHOSPHOTRANSFERASE
CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGAGGCA GCGCGGCTAT CGTGGCTGGC 5460 795bp=264 AMINO ACIDS & STOP CODON CACGACGGC GTTCCTTGCG CAGCTGTGCT CGACGTTGTC ACTGAAGCGG GAAGGGACTG 5520 GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCCTGCCGA 5580 GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT ACGCTTGATC CGGCTACCTG 5640 CCCATTCGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGGAAGCCGG 5700 TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG CTCGCGCCAG CCGAACTGTT 5760 CGCCAGGCTC AAGGCGCGCA TGCCCGACGG CGAGGATCTC GTCGTGACCC ATGGCGATGC 5820 CTGCTTGCCG AATATCATGG TGGAAAATGG CCGCTTTTCT GGATTCATCG ACTGTGGCCG 5880 GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT ACCCGTGATA TTGCTGAAGA 5940 GCTTGGCGGC GAATGGGCTG ACCGCTTCCT CGTGCTTTAC GGTATCGCCG CTTCCCGATTC 6000

FIG. 2D

STOP NEO GCAGCGCATC GCCTTCTTGA CGAGTTCTTC TGAGCGGGAC TCTGGGGTTC 6060 6043 4 GAAATGACCG ACCAAGCGAC GCCCAACCTG CCATCACGAG ATTTCGATTC CACCGCCGCC 6120 3' UNTRANSLATED NEO=173bp
TTCTATGAAA GGTTGGGCTT CGGAATCGTT TTCCGGGACG CCGGCTGGAT GATCCTCCAG 6180 CGCGGGGATC TCATGCTGGA GTTCTTCGCC CACCCCAACT TGTTTATTGC AGCTTATAAT 6240 GGTTACAAAT AAAGCAATAG CATCACAAAT TTCACAAATA AAGCATTTTT TTCACTGCAT 6300 SV40 POLY A EARLY=133bp |LINKER #13=19bp | TCTAGTTGTG GTTTGTCCAA ACTCATCAAT CTATCTTATC ATGTCTGGAT CGCGGCCGC5 6360 6349 50 ATCCCGTCGA GAGCTTGGCG TAATCATGGT CATAGCTGTT TCCTGTGTGA AATTGTTATC 6420 CGCTCACAAT TCCACACAAC ATACGAGCCG GAAGCATAAA GTGTAAAGCC TGGGGTGCCT 6480 AATGAGTGAG CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCGCTTTC CAGTCGGGAA 6340 ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC GGGGAGAGGC GGTTTGCGTA 6600 PVC 19
TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC 6660 GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG 6720 CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCGT 6780 6792=BACTERIAL ORIGIN OF REPLICATION
TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT CGACGCTCAA 6840 GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA GGCGTTTCCC CCTGGAAGCT 6900 CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC GCCTTTCTCC 6960 CTTCGGGAAG CGTGGCGCTT TCTCAATGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG 7020 TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC CGCTGCGCCT 7080 TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG 7140 CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA 7200 AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA 7260 AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAACAA ACCACCGCTG 7320 GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAA5 7380 AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAS 7440 GGATTITGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT 7500

FIG. 2E

STOP BETA LACTAMASE | GAAGTITIAA ATCAATCIAA AGTATATATG AGTAAACTIG GICTGACAGT TACCAATGCT 7560 TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG TTCATCCATA GTTGCCTGAC 7620 TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA 7680 TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC CAGCCAGCCG 7740 BETA LACTAMASE=861bp

GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAATT 7800 286 AMINO ACID & STOP CODON
GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTTGCC4 7860 TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT 7920 CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT 7980 TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG 8040 CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG 8100 AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG 8160 CGTCAATACG GGATAATACC GCGCCACATA GCAGAACITT AAAAGTGCTC ATCATTGGAA 8220 AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT 8280 AACCCACTCG TGCACCCAAC TGATCTTCAG GATCTTTTAC TTTCACCAGC GTTTCTGGGT 8340 GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT 8400 START BETA LACTAMASE

GAATACTCAT ACTCTTCCTT TITCAATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA 8460

8410 TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT 8520 TTCCCCGAAA AGTGCCACCT

FIG. 2F

LINKER #1= GACGTCGCGG	=15bp CCGCTCTAGG 15 6	CCTCCAAAAA	AGCCTCCTCA	CTACTTCTGG	AATAGCTCAG	60
AGGCCGAGGC	GGCCTCGGCC			TAGTCAGCCA	TGCATGGGGC	120
GGAGAATGGG	CGGAACTGGG	SV40 ORIG CGGAGTTAGG	IN=332bp GGCGGGATGG	GCGGAGTTAG	GGGCGGGACT	180
ATGGTTGCTG	ACTAATTGAG	ATGCATGCTT	TGCATACTTC	TGCCTGCTGG	GGAGCCTGGG	240
GACTTTCCAC	ACCTGGTTGC	TGACTAATTG	AGATGCATGC	TTTGCATACT	TCTGCCTGCT	300
GGGGAGCCTG	GGGACTTTCC	ACACCCTAAC	TGACACACAT	TCCACAGAAT 347 8	CER #2=13bp	360
AGTTATTAAT	AGTAATCAAT	TACGGGGTCA	TTAGTTCATA	GCCCATATAT	GGAGTTCCGC	420
GTTACATAAC	TTACGGTAAA	TGGCCCGCCT	GGCTGACCGC	CCAACGACCC	CCGCCCATTG	480
ACGTCAATAA	TGACGTATGT				TTGACGTCAA	540
TGGGTGGACT	CVM ATTTACGGTA	PROMOTER- AACTGCCCAC	ENHANCER=56 TTGGCAGTAC	S7bp ATCAAGTGTA	TCATATGCCA	600
AGTACGCCCC	CTATTGACGT	CAATGACGGT	AAATGGCCCG	CCTGGCATTA	TGCCCAGTAC	660
ATGACCTTAT	GGGACTTTCC	TACTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	720
ATGGTGATGC	GGTTTTGGCA	GTACATCAAT	GGGCGTGGAT	AGCGGTTTGA	CTCACGGGGA	780
TTTCCAAGTC	TCCACCCCAT	TGACGTCAAT	GGGAGTTTGT	TTTGGCACCA	AAATCAACGG	840
GACTTTCCAA	AATGTCGTAA			AAATGGGCGG	TAGGCGTGTA	900
CGGTGGGAGG	TCTATATAAG		#3=7bpj TACGTGAACC 934 5	GTCAGATCGC	CTGGAGACGC	960
Bgl CATCACAGAT	2 STA	ART LIGHT CH		ATURAL LEAD	ER=66bp	1020
	978 9					1020
GCTTCAGTCA	TAATGTCCAG	AGGACAAATT 1044 5 + 1	GTTCTCTCCC	AGTCTCCAGC	AATCCTGTCT	1080
GCATCTCCAG	GGGAGAAGGT		TGCAGGGCCA	GCTGAAGTGT	AAGTTACATC	1140
CACTGGTTCC	AGCAGAAGCC					1200
стббсттстб	LIGHT CHA	AIN VARIABLE TCGCTTCAGT	REGION 3181 GGCAGTGGGT	p 106 AMINO CTGGGACTIC	TTACTCTCTC	1260
ACCATCAGCA	GAGTGGAGGC	TGAAGATGCT	GCCACTTATT	ACTGCCAGCA	GTGGACTAGT	1320
AACCCACCCA	CGTTCGGAGG	GGGGACCAAG	CTGGAAATCA	BsiWI AACGTACGGT 62 3	GGCTGCACCA	1380
TCTGTCTTCA	TCTTCCCGCC	ATCTGATGAG	CAGTTGAAAT	CTGGAACTGC	CTCTGTTGTG	1440
TGCCTGCTGA	ATAACTTCTA	TCCCAGAGAG	GCCAAAGTAC	AGTGGAAGGT	GGATAACGCC	1500

FIG. 3A

				ACID & STOP		4560
LILLAAILUU	GTAACTUCLA	GUAGAGIGIC	ALAGAGLAGG	ACAGCAAGGA	CAGCACCTAC	1560
AGCCTCAGCA	GCACCCTGAC	GCTGAGCAAA	GCAGACTACG	AGAAACACAA	AGTCTACGCC	1620
TGCGAAGTCA STOP LIGHT	CCCATCAGGG	CCTGAGCTCG	CCCGTCACAA	AGAGCTTCAA	CAGGGGAGAG	1680
CHAIN Eco		LINKER ACGGTTACCA	#4=81bp ACTACCTAGA	CTGGATTCGT	GACAACATGC	1740
GGCCGTGATA	TCTACGTATG	ATCAGCCTCG	ACTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	1800
GTTTGCCCCT	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	TGTCCTTTCC	1860
TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	TCTGGGGGGT	1920
				ON REGION=2: ATAGCAGGCA		1980
GCGGTGGGCT	.CTATGGAACC 20	LINKER # AGCTGGGGCT 02 3	5=15bp CGACAGCTAT 2017 8	GCCAAGTACG	CCCCCTATTG	2040
ACGTCAATGA	CGGTAAATGG	CCCGCCTGGC	ATTATGCCCA	GTACATGACC	TTATGGGACT	2100
TTCCTACTTG				TACCATGGTG	ATGCGGTTTT	2160
GGCAGTACAT			ENHANCER=3: TTGACTCACG	GGGATTTCCA	AGTCTCCACC	2220
CCATTGACGT	CAATGGGAGT	TTGTTTTGGC	ACCAAAATCA	ACGGGACTTT	CCAAAATGTC	2280
			GCGGTAGGCG	TGTACGGTGG		2340
TAAGCAGAGC	INKER #6=7bj TGGGTACGTC 1 2 235B 9		GTGATCAGCA	CTGAACACAG	ACCCGTCGAC	2400
HEAVY CHAIN	GCCTCATCTT	THETIC & NA GCTCTTCCTT	TURAL LEADE GTCGCTGTTG	CTACGCGTGT	2457 8 CCTGTCCCAG 3 -2 -1 +1	2460
GTACAACTGC	AGCAGCCTGG	GGCTGAGCTG	GTGAAGCCTG	GGGCCTCAGT	GAAGATGTCC	2520
TGCAAGGCTT	CTGGCTACAC	ATTTACCAGT	TACAATATGC	ACTGGGTAAA	ACAGACACCT	2580
GGTCGGGGCC			= 363bp=121	AMINO ACID ATGGTGATAC	TTCCTACAAT	2640
CAGAAGTTCA	AAGGCAAGGC	CACATTGACT	GCAGACAAAT	CCTCCAGCAC	AGCCTACATG	2700
CAGCTCAGCA	GCCTGACATC	TGAGGACTCT	GCGGTCTATT	ACTGTGCAAG	ATCGACTTAC	2760
				CCACGGTCAC	ı	2820
<u>Nhe I</u> GCTAGCACCA	AGGGCCCATC	GGTCTTCCCC	CTGGCACCCT	CCTCCAAGAG	CACCTCTGGG	2880
GGCACAGCGG	CCCTGGGCTG	CCTGGTCAAG	GACTACTTCC	CCGAACCGGT	GACGGTGTCG	2940
TGGAACTCAG	HUM GCGCCCTGAC	AN GAMMA 1 CAGCGGCGTG	CONSTANT=9 CACACCTTCC	93bp CGGCTGTCCT	ACAGTCCTCA	3000
		FIC	G. $3B$			

330 AMINO ACID & STOP CODON
GGACTCTACT CCCTCAGCAG CGTGGTGACC GTGCCCTCCA GCAGCTTGGG CACCCAGACC 3060 TACATCIGCA ACGIGAATCA CAAGCCCAGC AACACCAAGG IGGACAAGAA AGCAGAGCCC 3120 AAATCTTGTG ACAAAACTCA CACATGCCCA CCGTGCCCAG CACCTGAACT CCTGGGGGGA 3:80 CCGTCAGTCT TCCTCTTCCC CCCAAAACCC AAGGACACCC TCATGATCTC CCGGACCCCT 3240 GAGGTCACAT GCGTGGTGGT GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG 3300 TACGTGGACG GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGAGGA GCAGTACAAC 3360 AGCACGTACC GTGTGGTCAG CGTCCTCACC GTCCTGCACC AGGACTGGCT GAATGGCAAG 3420 GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCCAGCCC CCATCGAGAA AACCATCTCC 3480 AAAGCCAAAG GGCAGCCCCG AGAACCACAG GTGTACACCC TGCCCCCATC CCGGGATGAG 3540 CTGACCAAGA ACCAGGTCAG CCTGACCTGC CTGGTCAAAG GCTTCTATCC CAGCGACATC 3600 GCCGTGGAGT GGGAGAGCAA TGGGCAGCCG GAGAACAACT ACAAGACCAC GCCTCCCGTG 3660 CTGGACTCCG ACGGCTCCTT CTTCCTCTAC AGCAAGCTCA CCGTGGACAA GAGCAGGTGG 3720 CAGCAGGGGA ACGTCTTCTC ATGCTCCGTG ATGCATGAGG CTCTGCACAA CCACTACACG 3780 STOP HEAVY CHAIN Bam HI LINKER #7=81bp CAGAAGAGCC TCTCCCTGTC TCCGGGTAAA TGAGGATCCG TTAACGGTTA CCAACTACCT 3840 3813 4 AGACTGGATT CGTGACAACA TGCGGCCGTG ATATCTACGT ATGATCAGCC TCGACTGTGC 3900 CTTCTAGTTG CCAGCCATCT GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG 3960 GTGCCACTCC CACTGTCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA 4020 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp GGTGTCATIC TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAAG GATTGGGAAG 4080 ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGA ACCAGCTGGG GCTCGACAGC 4140 GCTGGATCTC CCGATCCCCA GCTTTGCTTC TCAATTTCTT ATTTGCATAA TGAGAAAAAA 4200 AGGAAAATTA ATTTTAACAC CAATTCAGTA GTTGATTGAG CAAATGCGTT GCCAAAAAGG 4260 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp ATGCTTTAGA GACAGTGGTC TCTGCACAGA TAAGGACAAA CATTATTCAG AGGGAGTACC **432**0 CAGAGCTGAG ACTCCTAAGC CAGTGAGTGG CACAGCATTC TAGGGAGAAA TATGCTTGTC 4380 ATCACCGAAG CCTGATTCCG TAGAGCCACA CCTTGGTAAG GGCCAATCTG CTCACACAGG 4440 ATAGAGAGGG CAGGAGCCAG GGCAGAGCAT ATAAGGTGAG GTAGGATCAG TTGCTCCTCA 4500

FIG. 3C

				<u>JNTRA</u> NSLATEI		
CATTTGCTTC	TGACATAGTT	61611666A6 4525 6	CTTGGATAGC	4544 5	CAGGGCTGCG	4560
	AAACTTGACG	GCAATCCTAG	CGTGAAGGCT	GGTAGGATTT	TATCCCCGCT	#620
GCCATCATG 4626 7	T DHFR TTCGACCATT	GAACTGCATC	GTCGCCGTGT	CCCAAAATAT	GGGGATTGGC	4680
AAGAACGGAG	ACCTACCCTG	GCCTCCGCTC	AGGAACGAGT	TCAAGTACTT	CCAAAGAATG	4740
ACCACAACCT	CTTCAGTGGA	AGGTAAACAG	AATCTGGTGA	TTATGGGTAG	GAAAACCTGG	4800
TTCTCCATTC	DHFR=564	bp=187 AMIN TCGACCTTTA	IO ACID & ST AAGGACAGAA	OP CODON TTAATATAGT	TCTCAGTAGA	4860
GAACTCAAAG	AALLALLALG	AGGAGETCAT	THUTIGULA	AAAGTTTGGA	TGATGCCTTA	4920
AGACTTATTG	AACAACCGGA	ATTGGCAAGT	AAAGTAGACA	TGGTTTGGAT	AGTCGGAGGC	4980
AGTTCTGTTT	ACCAGGAAGC	CATGAATCAA	CCAGGCCACC	TTAGACTCTT	TGTGACAAGG	5040
ATCATGCAGG	' AATTTGAAAG	TGACACGTTT	TTCCCAGAAA	TTGATTTGGG	GAAATATAAA	5100
CTTCTCCCAG	AATACCCAGG	CGTCCTCTCT	GAGGTCCAGG	AGGAAAAAGG	CATCAAGTAT	5160
AAGTTTGAAG	TCTACGAGAA	STOP DHFR GAAAGACTAA 5140	CAGGAAGATG	ANSLATED DH CTTTCAAGTT	стстбстссс	5220
	TATGCATTTT	TATAAGACCA	TGGGACTTTT		LINKER #10 GATCAGCCTC 72 3	5280
=10bp _j GACTGTGCCT	TCTAGTTGCC	AGCCATCTGT	TGTTTGCCCC	TCCCCCGTGC	CTTCCTTGAC	5340
CCTGGAAGGT	BOVINE GROV	TH HORMONE				5400
TCTGAGTAGG	TGTCATTCTA	110100000	1000010000	LAGUALAGLA	LINKER #11	5460
	AATAGCAGGC	ATGCTGGGGA	TGCGGTGGGC	TCTATGGAAC 5		5520
=17bp TCGAGCTACT 5530		CTCAATTTCT	TATTTGCATA	ATGAGAAAAA	AAGGAAAATT	5580
AATTTTAACA	CCAATTCAGT	AGTTGATTGA	GCAAATGCGT	TGCCAAAAAG	GATGCTTTAG	5640
AGACAGTGTT	MOUSE BE	TA GLOBIN M			CATCACCGAA	5700
	•					
GACTCCTAAG	CCAGIGAGIG	GCACAGCATT	CTAGGGAGAA	ATATGCTTGT	CATCACCGAA	5/60
GCCTGATTCC	GTAGAGCCAC	ACCTTGGTAA	GGGCCAATCT	GCTCACACAG	GATAGAGAGG	5820
GCAGGAGCCA	GGGCAGAGCA	TATAAGGTGA	GGTAGGATCA	GTTGCTCCTC	ACATTTGCTT	5880
CTGACATAGT		LINKER #12=2 GCTTGGATCG	21bp STA	RT NEO	ATGGATTGCA	5940
2.3.3.11101	5896 7	232500	5917 8	2 3		JJ-0
CGCAGGTTCT	CCGGCCGCTT	GGGTGGAGAG	GCTATTCGGC	TATGACTGGG	CACAACAGAC	6000

FIG. 3D

AATCGGCTGC	TCTGATGCCG	CCGTGTTCCG	GCTGTCAGCG	CAGGGGGCGCC	CGGTTCTTTT	6060
NEOMYCIN TGTCAAGACC	PHOSPHOTRA GACCTGTCCG	NSFERASE=79 GTGCCCTGAA	5bP=264 AMI TGAACTGCAG	NO ACID & S' GACGAGGCAG	TOP CODON CGCGGCTATC	6120
GTGGCTGGCC	ACGACGGGCG	TTCCTTGCGC	AGCTGTGCTC	GACGTTGTCA	CTGAAGCGCG	6180
AAGGGACTGG	CTGCTATTGG	GCGAAGTGCC	GGGGCAGGAT	CTCCTGTCAT	CTCACCTTGC	6240
TCCTGCCGAG	AAAGTATCCA	TCATGGCTGA	TGCAATGCGG	CGGCTGCATA	CGCTTGATCC	6300
GGCTACCTGC	CCATTCGACC	ACCAAGCGAA	ACATCGCATC	GAGCGAGCAC	GTACTCGGAT	6360
GGAAGCCGGT	CTTGTCGATC	AGGATGATCT	GGACGAAGAG	CATCAGGGGC	TCGCGCCAGC	6420
CGAACTGTTC	GCCAGGCTCA	AGGCGCGCAT	GCCCGACGGC	GAGGATCTCG	TCGTGACCCA	6480
TGGCGATGCC	TGCTTGCCGA	ATATCATGGT	GGAAAATGGC	CGCTTTTCTG	GATTCATCGA	6540
ствтьсссьь	CTGGGTGTGG	CGGACCGCTA	TCAGGACATA	GCGTTGGCTA	CCCGTGATAT	6600
TGCTGAAGAG	CTTGGCGGCG	AATGGGCTGA	CCGCTTCCTC			6660
TCCCGATTCG	CAGCGCATCG	CCTTCTATCG	CCTTCTTGAC			6720
CTGGGGTTCG		CCAAGCGACG			TTTCGATTCC	6780
ACCGCCGCCT		UNTRANSLAT		TCCGGGACGC	CGGCTGGATG	6840
ATCCTCCAGC	GCGGGGATCT	CATGCTGGAG	TTCTTCGCCC	ACCCCAACTT 6885 6	GTTTATTGCA	6900
GCTTATAATG	GTTACAAATA	AAGCAATAGC	ATCACAAATT	TCACAAATAA	AGCATTTTTT	6360
	CTAGTTGTGG	Y POLYADENY TTTGTCCAAA			TGTCTGGATC	7020
LINKER #1 GCGGCCGCGA		AGCTTGGCGT	AATCATGGTC	ATAGCTGTTT	CCTGTGTGAA	7080
ATTGTTATCC		CCACACAACA	C 19 TACGAGCCGG	AAGCATAAAG	TGTAAAGCCT	7140
GGGGTGCCTA	ATGAGTGAGC	TAACTCACAT	TAATTGCGTT	GĆGCTCACTG	CCCGCTTTCC	7200
AGTCGGGAAA	CCTGTCGTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	7260
GTTTGCGTAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TOGGTOGTTO	7320
GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	ACGGTTATCC	ACAGAATCAG	7380
GGGATAACGC		ATGTGAGCAA			AACCGTAAAA	7440
ΔΕΓΡΡΕΡΕΤΤ		ACTERIAL ORI			Γ	7500

FIG. 3E

GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC 7560 CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG 7620 CCTITCTCCC TTCGGGAAGC GTGGCGCTTT CTCAATGCTC ACGCTGTAGG TATCTCAGTT 7680 CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC 7740 GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC 7800 CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG 7860 AGTICITGAA GIGGIGGCCI AACTACGGCI ACACTAGAAG GACAGIATII GGIATCICCG 7920 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAACAAA 7980 CCACCGCTGG TAGCGGTGGT TTTTTTGTTT GCAAGCAGCA GATTACGCGC AGAAAAAAA 8040 GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAACT 8100 CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG ATCCTTTTAA 8160 ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT 8220 BETA LACTAMASE ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTCGT TCATCCATAG 8280 TTGCCTGACT CCCCGTCGTG TAGATAACTA CGATACGGGA GGGCTTACCA TCTGGCCCCA &340 GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACC 8400 BETA LACTAMASE=861bp=286 AMINO ACID & STOP CODON AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT 8460 CTATTAATIG TIGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT TIGCGCAACG 8520 TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA 8580 GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG 8640 TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA 8700 TGGTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG 8760 TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA CCGAGTTGCT 8820 CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA AAAGTGCTCA 8880 TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA 8940 GGTCGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTTACT TTCACCAGCG 9000 TTTCTGGGTG AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC 9060 GGAAATGTIG AATACT<u>CAT</u>A CICTICCTII TICAATATIA TIGAAGCATI TATCAGGGTI **9120** ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTC **9180** CGCGCACATT TCCCCGAAAA GTGCCACCT

FIG. 3F

LEADER


-20 -15 FRAME 1 Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser Val ATG GAT TTT CAG GTG CAG ATT ATC AGC TTC CTG CTA ATC AGT GCT TCA GTC 996 1005 1014 FR1 -1 | +1 Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser ATA ATG TCC AGA GGA CAA ATT GTT CTC TCC CAG TCT CCA GCA ATC CTG TCT GCA TCT 1065 1074 1038 1047 1056 20 23 24 CDR1 27/29 30 34 Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Val Ser Tyr Ile His CCA GGG GAG AAG GTC ACA ATG ACT TGC AGG GCC AGC TCA AGT GTA AGT TAC ATC CAC 1104 1131 1140 1095 1113 1122 FR2 40 45 49 | 50 Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn TGG TTC CAG CAG AAG CCA GGA TCC TCC CCC AAA CCC TGG ATT TAT GCC ACA TCC AAC 1152 1161 1170 1179 1188 60 FR3 65 Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser CTG GCT TCT GGA GTC CCT GTT CGC TTC AGT GGC AGT GGG TCT GGG ACT TCT TAC TCT 1209 1218 1227 1236 1245 80 85 88 89 90 Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gir. Trp CTC ACC ATC. AGC AGA GTG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG 1275 1284 1293 1302 97 198 CDR3 95 100 FR4 Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ACT AGT AAC CCA CCC ACG TTC GGA GGG GGG ACC AAG CTG GAA ATC AAA 1341 1350 1332 1359 1323


FIG. 4


LEADER

-15 -10 FRAME 1 Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg Val ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT GTC GCT GTT GCT ACG CGT GTC Leu Ser Gin Val Gin Leu Gin Gin Pro Gly Ala Siu Leu Val Lys Ala Gly Ala Ser CTG TCC CAG GTA CAA CTG CAG CAG CCT GGG GCT GAG CTG GTG AAG CCT GGG GCC TCA 30 | 31 CDR1 35 136 Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His iTrp GTG AAG ATG TCC TGC AAG GCT TCT GGC TAC ACA TTT ACC AGT TAC AAT ATG CAC TGG 40 FR2 49 | 50 52 52A 53 54 Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn GTA AAA CAG ACA CCT GGT CGG GGC CTG GAA TGG ATT GGA GCT ATT TAT CCC GGA AAT CDR2 65 | 66 FR3 Gly Asp Thr Ser Tyr Ash Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys GGT GAT ACT TCC TAC AAT CAG AAG TTC AAA GGC AAG GCC ACA TTG ACT GCA GAC AAA 82 82A 82B 82C 83 Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC 94|95 CDR3 100 100A 100B 100C 100D 101 |102 103 Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly TAT TAC TGT GCA AGA TCG ACT TAC TAC GGC GGT GAC TGG TAC TTC AAT GTC TGG GGC 105 FR4 Ala Gly Thr Thr Val Thr Val Ser Ala GCA GGG ACC ACG GTC ACC GTC TCT GCA

FIG. 5











ANTIBODY


FIG. 8





















FIG. 14A



64